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1 Introduction  
1.1 Diagnosis, histopathology, treatment, and prognosis of ovarian cancer  
Ovarian cancer is one of the most common malignancies and is the eighth leading cause 
of cancer-related death worldwide among women, followed by breast, lung, colorectum, 
cervix uteri, stomach, liver, and pancreas cancers (Bray et al., 2018). In 2018, 295,414 
females were diagnosed with ovarian carcinoma and 184,799 patients died from this 
disease throughout the world (Bray et al., 2018). Globally, the highest age-standardized 
incidence rates of ovarian cancer were present in Europe (9.9 per 100,000), where it 
ranked as the fifth most commonly diagnosed carcinoma among women, followed by 
cancers of breast, colorectum, lung, and uterus (Ferlay et al., 2015). 
Known factors leading an increased risk of developing ovarian cancer are familial 
genetic syndromes, pelvic inflammatory disease (borderline tumors), endometriosis, 
smoking, obesity, postmenopausal hormone therapy (particularly for more than five 
years), as well as older age at menopause and younger age at menarche. In contrast, 
long-term oral contraceptive use, pregnancy, and breastfeeding have been viewed as 
protective factors for this disease (Doubeni et al., 2016; Webb and Jordan, 2017; Lisio 
et al., 2019). There is evidence that ovarian cancer is most frequently diagnosed among 
women aged 55-64 (median age 63) and the highest death rate is among women aged 
65-74 (median age 70) (Noone et al., 2018). Additionally, during the clinical practice, 
several biological and clinical variables have been identified as prognostic predictors 
for ovarian cancer patients, such as age, FIGO (the Féderation Internationale de 
Gynécologie et d’Obstétrique) stage, histological subtype, nuclear grade, residual 
tumor mass after debulking surgery, ascites fluid volume, and performance status 
(Berman, 2003).  
According to the guidelines of FIGO and the TNM classification system (T: the primary 
tumor; N: regional lymph nodes; M: distant metastasis) (see Appendix 9.1), staging is 
determined at the time of initial diagnosis and serves as the major prognostic factor in 
ovarian cancer (Mutch and Prat, 2014). Patients afflicted with early-stage (FIGO I) 
ovarian cancer have a 5-year survival rate of up to 92.3%, which considerably drops to 
29.2% for advanced stage (FIGO III/IV) patients (Noone et al., 2018). Unfortunately, 
only 14.9% of ovarian cancer patients are diagnosed at FIGO I, while the majority of 
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patients (up to 59%) present at advanced stages (FIGO III or IV), resulting in the overall 
poor prognosis and high mortality rate (Noone et al., 2018). Thus, early detection is the 
key to improve the rate of survival of ovarian cancer. 
Nevertheless, early diagnosis of ovarian cancer is difficult, mainly due to the fact that 
the early stage of this disease is generally asymptomatic or presents nonspecific and/or 
low sensitive symptoms, such as abdominal pain/bloating, pelvic pain, constipation, 
fatigue, or urinary symptoms (Paulsen et al., 2005). To date, transvaginal 
ultrasonography and use of the blood assay for CA125 are major screening approaches 
for ovarian cancer in the clinical practice. However, both methods present limited 
sensitivity and specificity for early detection of this disease. For example, these two 
screening strategies failed to diminish the mortality risk in a U.S. clinical trial (Buys et 
al., 2011). Moreover, pelvic examination is also recommended as a screening strategy 
for early detection of ovarian cancer. Similarly, up to now, no study presented that 
pelvic exam could provide a benefit for ovarian cancer morbidity or mortality 
(Guirguis-Blake et al., 2017). Therefore, it is not surprising that the mortality of this 
gynecologic malignancy decreased only slightly over the past forty years (Kurman, 
2013). Based on this, effective screening strategies for the early diagnosis of ovarian 
cancer are in demand. 
After diagnosis, the following treatment options are recommended for the ovarian 
cancer patients. The present cutting-edge treatment modalities comprise surgery, 
platinum-/taxane-based chemotherapy, sometimes plus radiotherapy, depending upon 
tumor stage and the extent of surgical debulking (Jelovac and Armstrong, 2011; Sundar 
et al., 2015). Comprehensive staging laparotomy followed by platinum-containing 
combined chemotherapy is potentially curative for women with early-stage ovarian 
cancer, i.e. the disease is confined to ovaries (FIGO I) or pelvis (FIGO II). Numerous 
retrospective studies and meta-analyses have indicated that the amount of post-
operative residual tumor mass is the strongest independent prognostic factor (Burges 
and Schmalfeldt, 2011; Dorn et al., 2015). Furthermore, the survival of ovarian cancer 
patient has been proven to benefit from increasing surgical debulking rates (Aletti et al., 
2006; Chi et al., 2006; Winter et al., 2007; Chi et al., 2009; Du Bois et al., 2009; Elattar 
et al., 2011). Additionally, it has been shown that late-stage ovarian cancer patients with 
a small volume of residual tumor mass after primary surgery, followed by systemic 
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chemotherapy, have a better outcome than those with a larger volume of residual tumor 
mass after initial surgery (Pölcher et al., 2014). Thus, for the subset of ovarian cancer 
patients with advanced stages, surgical cytoreduction aims to reach maximal resection 
of all visible tumors (Aebi and Castiglione, 2009; Burges and Schmalfeldt, 2011; 
Pölcher et al., 2014). Based on this, for more than 30 years, the maximum debulking 
surgery following platinum-/taxane-based chemotherapy has been acknowledged as the 
standard therapeutic management of advanced ovarian cancer (Kim et al., 2012). 
Meantime, many antitumor agents, involving angiogenesis inhibitors and molecular-
targeted agents, or combined treatment schemes have been investigated in clinical trials. 
However, both therapeutic options have not obviously improved the overall survival 
rate of this lethal gynecologic malignancy (Davis et al., 2014). 
Ovarian cancer is a heterogeneous disease encompassing diverse subtypes, with widely 
differing morphology, molecular-genetic features, and clinical behavior (Table 1). 
Morphologically, ovarian cancer is broadly categorized into epithelial ovarian cancer 
(EOC) and non-epithelial ovarian cancer (NEOC) (Kim et al., 2018). Only a small 
fraction (2%) of ovarian cancer cases are NEOC, including two types: germ-cell tumors 
and sex cord-stromal tumors (Koulouris and Penson, 2009; Boussios et al., 2016; Ray-
Coquard et al., 2018). The majority (98%) of ovarian cancer are EOC (Bast et al., 2009; 
Jayson et al., 2014), containing four well-defined histological subtypes: serous (75%), 
endometrioid (10%), clear cell (10%) and mucinous carcinomas (3%) (Prat, 2014; 
Sundar et al., 2015). Based on histopathology and molecular genetic changes, EOC, 
which comprises heterogeneity of clinicopathologic features and behavior, is 
subdivided into type I and type II (Kurman et al., 2014). The type I tumor category, 
accounting for 25% of EOC, comprises subtypes of low-grade serous, low-grade 
endometrioid, clear-cell, mucinous, and transitional cell (Brenner) carcinomas (Jayson 
et al., 2014; Au et al., 2015). These neoplasms mostly derive from pre-malignant or 
borderline lesions and are characterized by slow tumor growth (Shih and Kurman, 2004; 
Jones and Drapkin, 2013; Kurman and Shih, 2016). Moreover, the type I ovarian tumors 
are genetically stable, harbouring somatic mutations of genes encoding protein kinases, 
such as KRAS, BRAF, CTNNB1, and PIK3CA (Shih and Kurman, 2004; Jones and 
Drapkin, 2013; Kurman and Shih, 2016), but not TP53 or BRCA (Bashashati et al., 
2013). In contrast, the type II ovarian tumors are depicted as high-grade, more 
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aggressive, and genetically unstable. They are predominantly diagnosed at an advanced 
stage (FIGO stage III or IV: 60–80%), resulting in poor outcome (Seidman et al., 2004; 
Kurman and Shih, 2010; Lengyel, 2010; Peres et al., 2019). The type II ovarian cancer 
comprises high-grade serous, high-grade endometrioid, undifferentiated carcinomas, as 
well as malignant mixed-mesodermal tumors (Kurman and Shih, 2008; Lim and Oliva, 
2013). High-grade serous ovarian cancer (HGSOC) is the prototype of type II ovarian 
neoplasms with a high-frequency TP53 mutations (>80% of cases) (Cho and Shih, 
2009), representing about 75% of all EOCs (Karst and Drapkin, 2010; Jayson et al., 
2014) and accounting for a large majority (70–80%) of deaths from all ovarian cancer 
(Bowtell et al., 2015; Kurman and Shih, 2016). Upon that, the present study focused on 
this most common and lethal subtype of ovarian cancer. 
 
Table 1. Histopathological subtypes of ovarian cancer  
Ovarian cancer Subtype 
NEOC (2%) germ-cell tumors  sex cord-stromal tumors 
EOC (98%) 
Type I (25%) 
low-grade serous tumors  
low-grade endometrioid tumors 
clear-cell tumors  
mucinous tumors 
transitional cell (Brenner) tumors 
Type II (75%) 
high-grade serous tumors 
high-grade endometrioid tumors 
undifferentiated carcinomas tumors 
malignant mixed-mesodermal tumors 
NEOC: non-epithelial ovarian cancer; EOC: epithelial ovarian cancer. 
 
Due to the heterogeneity of distinct subtypes, the lack of obvious symptoms in early 
stage, the inefficient primary debulking surgery and the rapid development of chemo-
resistance, the majority of patients are diagnosed at advanced stages and have a high 
mortality rate (Jemal et al., 2011; Pölcher et al., 2014). The present treatment for 
patients afflicted with ovarian cancer is based on traditional cancer factors, such as 
tumor stage and reductive surgery. Moreover, most of the tumor biomarkers are not 
cancer and/or tumor-type specific for ovarian cancer detection, diagnosis, and 
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prognosis. Therefore, new specific tumor biomarkers for different subgroups of ovarian 
cancer to predict the course of disease and therapy response are urgently needed. 
1.2 Diagnosis, histopathology, treatment, and prognosis of breast cancer  
Globally, breast cancer is the most frequently diagnosed carcinoma and the leading 
cause of cancer-related death among females (Bray et al., 2018). In 2018, approximately 
2.1 million new cases were diagnosed with breast cancer worldwide and 626,679 
patients died from this disease (Bray et al., 2018). Numerous environmental and 
lifestyle factors have been recognized to increase the risk of breast cancer. In the clinical 
practice, more than 80% breast cancer cases are diagnosed among women aged 50 or 
older (Kamińska et al., 2015) and accordingly age is documented as one of the most 
important risk factors (Justo et al., 2013; Sun et al., 2017). Other known risk factors 
include gender, family history, hormone therapy, physical inactivity, alcohol, smoking, 
overweight and obesity (Kolak et al., 2017). Moreover, reproductive factors also 
increase the possibility of breast cancer, such as delayed childbearing, early menarche, 
and late menopause (Jerônimo et al., 2017). Additionally, various gene mutations and 
abnormal gene amplifications have been determined to facilitate the initiation and 
progression of breast cancer, e.g. BRCA 1/2, c-Myc, and the Ras gene family (Jerônimo 
et al., 2017).  
The mortality rate of breast cancer has been reduced in the past 30 years due to earlier 
detection and improved treatment options (Berry et al., 2005). The screening 
methodologies commonly used for breast cancer detection include breast self-
examination, mammography, ultrasonography, magnetic resonance imaging, and blood 
testing of tumor markers (Kolak et al., 2017; Akram et al., 2017). Mammography, which 
has been proven to decrease breast cancer mortality, is regarded as the mainstay of 
breast cancer imaging strategies, showing high sensitivity (77-95%) and excellent 
specificity (94-97%) (Humphrey et al., 2002; Berry et al., 2005). Furthermore, the 
addition of digital breast tomosynthesis was found to again remarkably increase the 
cancer detection rate and to diminish the rate of false-positive cases (Friedewald et al., 
2014).  
Besides the screening strategies, the continuous improvement of breast cancer therapies 
is another key factor to reduce the mortality rate. In breast cancer management, surgery 
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is the foremost treatment for patients without distant metastasis, including lumpectomy 
(breast-conserving surgery), mastectomy as well as reconstructive surgery. Moreover, 
surgery reveals the histologic grade and tumor stage, which both play crucial roles in 
the prediction of patient prognosis (Akram et al., 2017; Martei et al., 2018). 
Additionally, systemic therapy is also indispensable, including chemotherapy 
(neoadjuvant/adjuvant), endocrine therapy, and HER2-directed therapy (Harbeck and 
Gnant, 2017). Neoadjuvant chemotherapy is frequently applied to increase possibilities 
of breast conservation for females with the following indications: larger tumor size (> 
5cm), tumor fixed to the chest wall, locally advanced disease, and inflammatory breast 
cancer (McDonald et al., 2016). Furthermore, postoperative radiation therapy has been 
verified to be beneficial by randomized trials, showing an improvement in local-
regional control and reduction in the recurrence and mortality rates in this tumor entity 
(Correa et al., 2010; Darby et al., 2011; McCormick et al., 2015).  
However, these managements are not always efficacious owing to the fact that breast 
cancer is a very heterogeneous disease comprising numerous subtypes, which are 
distinct in biology, molecular features, clinical behaviors, treatment sensitivity and 
prognosis (Perou et al., 2000; Geyer et al., 2009). Breast cancer is clinically categorized 
according to the TNM-staging system (see Appendix 9.2), which is based on the 
primary tumor size (T), regional lymph node status (N), and distant metastasis (M) 
(Hortobagyi et al., 2017) (www. cancerstaging.org). Histologically, breast cancer can 
be classified into ductal carcinoma and lobular carcinoma, which are the two major 
subtypes and make up 80% of malignant breast tumors (Akram et al., 2017). The very 
rare subtypes (20%) include medullary carcinoma, mucinous carcinoma, tubular 
carcinoma, inflammatory breast cancer and Paget’s disease of the breast (Akram et al., 
2017).  
Several pathological markers have been extensively studied to characterize molecular 
subtypes of breast cancer, including estrogen receptor (ER), progesterone receptor (PR), 
human epidermal growth factor receptor 2 (HER2) and the tumor proliferation factor 
Ki67, which are clinically used to guide therapeutic decisions and predict patient 
outcome. ER and PR belong to the nuclear receptor superfamily and the abnormal 
expression of both receptors has been implicated in breast cancer tumorigenesis and 
development (Lanari and Molinolo, 2002). Overexpression of HER2 has been observed 
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in approximately 15-30% of breast cancer cases and associated with an increased risk 
of relapse and shortened survival (Moasser, 2007; Ross et al., 2009; Krishnamurti and 
Silverman, 2014).  
Additionally, it has been recognized that expression patterns of tumor-related genes are 
associated with breast cancer progression through modulation of the cell cycle, invasion, 
proliferation, and angiogenesis (Perou et al., 2000; Van't Veer et al., 2002). Thus, the 
molecular classification of breast cancer, which is more efficacious than the traditional 
TNM classification system, was established in daily clinical practice for planning 
patient-tailored therapy treatment (Sørlie et al., 2001; Merino et al., 2017). Based on 
the above-named immunochemistry markers, breast cancer is categorized into four 
subtypes (Table 2), including luminal A, luminal B, HER2-enriched and triple-negative 
breast cancer (TNBC) (Senkus et al., 2015; Merino et al., 2017).  
 
Table 2. Molecular subtypes of breast cancer and recommended therapies 
Subtype Pathological markers Recommended therapies 
Luminal A 
ER positive 
HER2 negative 
Ki67 low 
PR high (> 20%) 
low-risk molecular signature (if 
available) 
endocrine therapy alone in the 
majority of patients; 
chemotherapy for cases with 
high-risk factors (high tumor 
burden; grade 3) 
Luminal B 
 
HER2-
negative 
ER positive 
HER2 negative 
Ki67 high or PR low (≤ 20%) 
high-risk molecular signature (if 
available) 
endocrine therapy  
plus chemotherapy  
for the majority of patients 
HER2-
positive 
ER positive 
HER2 positive 
any Ki67 
any PR 
endocrine therapy  
plus chemotherapy 
plus HER2 target therapy  
for all patients 
HER2-enriched HER2-positive ER and PR absent 
chemotherapy 
plus HER2 target therapy 
Triple-negative ER and PR absent HER2 negative chemotherapy 
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 2 
receptor. Adapted from Senkus et al. 2015 and Merino et al. 2017. 
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Luminal A accounts for almost 50% of all breast cancers and is normally of low 
histological grade, having the most favorable prognosis with 5-year survival rates of 
80% (Sørlie et al., 2001; Trop et al., 2014). The incidence of luminal B is around 15%, 
with 5-year survival rates of 40% (Sørlie et al., 2001; Trop et al., 2014). According to 
the current treatment guidelines for all luminal subtypes with hormone receptor-
positive, the standard treatment is 5-years adjuvant endocrine therapy as monotherapy 
or after chemotherapy, including selective estrogen receptor modulators (e.g. tamoxifen) 
and aromatase inhibitors (e.g. anastrozole) (Harbeck and Gnant, 2017). The HER2-
enriched subtype, 15-30% of all breast tumors (Wang et al., 2008), is usually of high or 
intermediate histological grade and has a relative unfavorable outcome (Youk et al., 
2012). Before introduction of HER2-targeting therapy, 5-year survival rates of this 
subtype were around 31% (Sørlie et al., 2001). Anti-HER2 treatment, such as the 
monoclonal antibody trastuzumab (Herceptin®) and the tyrosine kinase inhibitor 
lapatinib (Tykerb®), decreases the risk of relapse as well as tumor-induced death and 
improves 5-year survival rates up to 90% (Brown-Glaberman et al., 2014). Moreover, 
the combination of anti-HER2 treatment and chemotherapy is recommended as the 
first-line treatment for breast cancer patients with HER2-overexpression (Romond et 
al., 2005; Harbeck and Gnant, 2017). 
TNBC accounts for up to 17% of primary breast cancers and is more commonly found 
in females younger than 50 years old (Foulkes et al., 2010). Histologically, the common 
features of TNBC comprise high nuclear grade, increased mitotic activity, central 
necrosis, enhanced tumor proliferation rate, as well as conspicuous lymphocytic 
infiltrate and fibrosis (Livasy et al., 2006; Elsawaf and Sinn, 2011). Clinically, TNBC 
shows a more aggressive phenotype with large tumor size, axillary infiltration and 
frequent visceral metastases (Choi et al., 2011; Park et al., 2012). Patients with TNBC 
have an elevated risk of recurrence during the first 1-3 years after diagnosis and an 
increased 5-year survival rate, compared to patients with other molecular subtypes 
(Dent et al., 2007; Pogoda et al., 2013). Last but not least, only about 10% of TNBC 
patients are diagnosed at an early stage (grade I, T1N0) (Badve et al., 2011), which also 
contributes to the poor prognosis (Kaplan et al., 2009).  
Furthermore, unlike ER/PR positive or HER2-overexpressing breast carcinomas, 
TNBC is characterized by a negative profile of ER, PR, and HER2, suggesting that the 
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available anti-targeted therapy has very limited or no impact on this entity. As shown 
in Table 2, besides surgery and radiotherapy, anthracycline-taxane-based chemotherapy 
is the only option for TNBC patients (Foulkes et al., 2010). Therefore, patients with 
TNBC have the worst outcome among all breast cancer subtypes (Foulkes et al., 2010). 
Thus, the identification of new biomarkers for the improvement of the therapeutic 
management of patients with TNBC is in demand. 
1.3 Kallikrein-related peptidases (KLKs) 
The original definition of kallikreins included two serine proteinases, plasma kallikrein 
(KLKB1) and tissue kallikrein (KLK1), responsible for proteolytically releasing kinin 
peptides from kininogens (Werle et al., 1969). KLKB1 differs from KLK1 in that it 
spans 15 exons and 14 introns and is located on chromosome 4q34-35 (Beaubien et al., 
1991; Bhoola et al., 1992; Sainz et al., 2007). Furthermore, KLKB1 is generated by the 
liver and is then secreted into the blood circulation system, where it is involved in 
activating clotting, fibrinolysis, and inflammation (Lawrence et al., 2010). As the 
founding member of the kallikrein-related peptidase family, KLK1 was discovered 
from pancreatic extracts already in the 1930s and was found to have kininogenase 
activity (Kraut et al., 1930; Werle et al., 1969). Subsequently, 14 orthologic kallikrein 
genes (KLK2-15) were identified, encoding serine proteases with conserved structures. 
However, unlike KLK1, KLK2-15 lack the enzyme activity to release kinin peptides 
from kininogens (Lundwall et al., 2006). Therefore, they were formally named 
kallikrein-related peptidases. 
The KLK gene family, located on the long arm of human chromosome 19q13.4 (Figure 
1A), is the largest contiguous cluster of serine proteases in the human genome (Prassas 
et al., 2015). This gene family is composed of 15 members, which are tightly arrayed 
in a tandem cluster without intervention of non-KLK gene. All 15 members share 
distinct sequence similarity (Figure 2): KLK1-3 share 61-79% sequence similarity to 
each other, while for KLK4-15 the similarity is 38-57% (Goettig et al., 2010). Based 
on that, KLK1-3 were named the classical KLKs, while KLK4-15 were the new KLKs. 
Furthermore, all KLK genes share many common genomic features (Figure 1B): all 
contain 5’ and 3’- untranslated region (UTR), five coding exons and four conserved 
introns (intron phases: I, II, I, 0) (Dong et al., 2014). Most KLK genes have one or two 
additional non-coding exons in the 5’UTR. Except for KLK2 and KLK3, the direction 
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of transcription of all KLK genes is from telomere to centromere (Paliouras and 
Diamandis, 2006). The coding exon 1 harbors the start codon and 5’UTR, while the 
termination codon and 3’UTR are in the coding exon 5. The codons for the three amino 
acids of the serine-type catalytic triad, histidine (His), aspartic (Asp), and serine (Ser), 
are highly conserved and located in coding exons 2, 3 and 5, respectively (Clements et 
al., 2001; Lawrence et al., 2010). In contrast to the coding exons, the untranslated 
regions of KLKs are more variable in length (ranging from 4.3 to 10.5 kb) and 
sequences (Kryza et al., 2016). To date, approximately 80 alternative mRNA splicing 
variants, which encode structurally and functionally unique proteins, have been 
described for KLKs (Lai et al., 2016).  
 
Figure 1. Gene, mRNA, and protein characteristics of KLKs 
A. The KLK gene family is located on chromosome 19q13.4 and flanked by the genes 
encoding testicular acid phosphatase (ACPT) and sialic acid-binding Ig-like lectin 9 
(SIGLEC9). It encompasses 15 members and representing the largest contiguous cluster of 
serine proteases in the human genome. B. Generally, KLKs contain 5 coding exons (dark 
gray boxes), where exon 2 carries catalytic His52, exon 3 carries Asp102, and exon 5 carries 
Ser195, as exemplified here by KLK1 mRNA. C. KLKs are firstly synthesized as pre-pro-
enzymes comprising a signal peptide (pre-), a pro-peptide (pro-) and a serine protease 
domain responsible for the catalytic activity. The figure is taken and adapted from Kalinska 
et al. 2016.  
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Figure 2. Sequence alignment of human KLKs with bovine chymotrypsin (bCTRA)  
All 15 members share a great similarity in sequence. The classical KLKs (KLK1-3) share 
61-79% sequence similarity to each other, while the similarity for the new KLKs (KLK4-15) 
is 38-57%. Highly conserved residues are shown with a grey background. Residue 16 
position when the propeptide is cleaved off is shown with a blue background. The figure is 
taken and adapted from Goettig et al., 2010. 
 
Human KLK gene expression is modulated by numerous factors, e.g. steroid hormones, 
which influence various signaling pathways (Shaw and Diamandis, 2008). For example, 
KLK4 is sensitive to androgen in prostate (Nelson et al., 1999) and breast cancer cell 
lines (Yousef et al., 1999) and to estrogen in endometrial cell lines (Myers and Clements, 
2001). KLK12 is responsive to androgen and progestin in prostate cancer cell lines and 
to estrogen as well as progestin in breast cancer cell lines (Yousef et al., 2000). 
Furthermore, it is highlighted that single nucleotide polymorphisms (SNPs) are 
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involved in modulation of KLKs expression and the proteolytic activity of KLK 
proteases (Lai et al., 2007). Moreover, epigenetic-related mechanisms, like histone 
modification, DNA methylation, and miRNA-mediated control of mRNA levels, have 
been demonstrated to affect the transcriptional and post-transcriptional regulation of 
KLKs (Pasic et al., 2012; Samaan et al., 2014; Pasic et al., 2015). 
Based on the structural organization and proteolytic mechanism, human KLKs belong 
to the chymotrypsin-like S1 family of serine peptidases and are secreted as trypsin- or 
chymotrypsin-like serine endopeptidases of around 25-30 kDa (Lawrence et al., 2010). 
KLKs are firstly synthesized as single-chain pre-pro-enzymes comprising three 
domains (Figure 1C): (i) the N-terminal signal peptide (pre-domain) with 16-33 amino 
acids, directing pre-pro-enzymes into the endoplasmic reticulum for secretion; (ii) the 
pro-peptide (pro-domain) with 3-37 amino acids, rendering them as inactive precursors; 
(iii) the KLK core domain (mature form) with 227-252 amino acids, containing the 
invariant catalytic triad (His, Asp, Ser), responsible for the catalytic activity (Avgeris 
and Scorilas, 2016). After activation, the majority of KLKs (KLK1-2, KLK4-6, KLK8, 
and KLK10-15) exhibit a trypsin-like activity, while KLK3, KLK7, and KLK9 possess 
a chymotrypsin-like activity with regard to substrate specificity (Lawrence et al., 2010). 
The activity of KLKs is modulated by multiple mechanisms and factors, comprising 
zymogen activation cascades, endogenous KLK inhibitors and micro-environmental 
pH (Goettig et al., 2010). Activation of pro-KLKs is a crucial process with regard to 
modulating active KLK levels in human tissues (Yousef and Diamandis, 2002). Guided 
by the single peptide, the newly synthesized inactive pre-pro-KLKs are secreted into 
the extracellular space after, in most cases, being glycosylated in the endoplasmic 
reticulum and Golgi apparatus (Guo et al., 2014). For activation and conversion to the 
mature forms, the propeptides of pro-KLKs have to be proteolytically removed (Kryza 
et al., 2016). This step is achieved by a trypsin-like cleavage after an arginine or a lysine 
residue for all KLKs, with the exception of KLK4 which is activated after a glutamine 
residue (Kalinska et al., 2016; Kryza et al., 2016). The pro-KLK-activating proteinases 
comprise plasmin, plasma kallikrein, urokinase-type plasminogen activator (uPA), 
factor Xa, thrombin, and matrix metalloproteinases (MMPs) (Yoon et al., 2008, 2013). 
Furthermore, Yoon et al. (2007) have identified the interaction profiles of KLKs, which 
may lead to proteolytic cascades as seen in the skin for KLK5, 7, 14 and others (Prassas 
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et al., 2015). In addition, KLK2, KLK6, and KLK13 have been reported to be 
autocatalytically activated (Yoon et al., 2007).  
The human tissue proteome data, based on an integrated omics approach, shows that 
KLKs are expressed with distinct expression profiles in diverse human tissues (Uhlén 
et al., 2015; Loessner et al., 2018). For example. KLK1 is highly expressed in kidney 
and pancreas (Lawrence et al., 2010), whereas KLK2 and KLK3 are two of the most 
abundant proteins in the prostate (Stanbrough et al., 2006). Nevertheless, none of KLKs 
is completely tissue-specific and different KLKs are usually observed to be expressed 
in the same tissues with distinct expression levels (Lawrence et al., 2010). Intriguingly, 
many KLKs are co-expressed in the same tissues, e.g. KLK2-4 show parallel expression 
pattern in the prostate, suggesting that these KLKs may be involved in enzymatic 
cascade reactions (Lawrence et al., 2010).  
KLKs are widely expressed in a variety of human tissues and are secreted into majority 
of physiological fluids (Kalinska et al., 2016), indicating that KLKs broadly participate 
in physiologic and pathological processes. Indeed, multiple studies have revealed the 
well-characterized roles of KLKs in various mechanistic pathways, such as the roles of 
KLK5 and KLK7 in desquamation of the skin (Yamasaki et al., 2006; Lundwall and 
Brattsand, 2008), of KLK3 in semen liquefaction (Pampalakis and Sotiropoulou, 2007), 
of KLK4 in the formation of tooth enamel (Bartlett, 2013) and of KLK6 in 
neuroinflammation (Ashby et al., 2010).  
1.4 Kallikrein-related peptidases in carcinoma 
In tumor research, the KLK family became more well-known, after KLK3 was shown 
to be remarkably associated with prostate carcinoma (Catalona et al., 1994). KLK3, 
also known as prostate-specific antigen (PSA), is a powerful biomarker for diagnosis 
and motility in prostate cancer. Therefore, expression of other KLK family members 
was extensively studied to determine their possible functions in neoplastic diseases. 
Indeed, nearly all KLKs have been found to be dysregulated in various cancer types, 
like lung, prostate, breast, ovarian and gastric cancer (Clements et al., 2004; Avgeris et 
al., 2012; Dorn et al., 2014; Scorilas and Mavridis, 2014). Moreover, KLKs have been 
shown to be involved in cancer progression (Sotiropoulou et al., 2009; Fuhrman-Luck 
et al., 2014; Yu et al., 2014). Previous investigations have shown that KLKs, as secreted 
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peptidases, could modulate various molecular signaling pathways in the tumor 
microenvironment, cleaving growth factors, cell surface receptors, and/or extracellular 
matrix (ECM) proteins. Thus, KLKs can positively or negatively influence tumor 
growth, metastasis, invasion, and chemoresistance (Lawrence et al., 2010; Kryza et al., 
2016).  
1.4.1 Roles of KLKs in tumor growth 
As mentioned above, KLKs have been shown to regulate tumor growth through 
modulating diverse signaling cascade pathways. The protease-activated receptor (PAR) 
family (PAR1-4) has been demonstrated to accelerate multiple intracellular signaling 
networks, thus contributing to a number of physiological and pathological processes 
(Gieseler et al., 2013). Previous studies found that several KLKs could initiate trans-
membrane signal transduction by activating PARs via proteolytic cleavage of the 
extracellular N-terminus, thus revealing a tethered ligand initiating cell signaling (Yu 
et al., 2014). For example, KLK14 could promote proliferation of colon cancer cells by 
initiating PAR2 and the downstream mitogen-activated protein kinase (MAPK) 
pathway (Gratio et al., 2011; Chung et al., 2012). In prostate cancer cells, KLK2 is able 
to activate PAR1 by modulating the extracellular signal-regulated kinase signaling, 
while KLK4 modulates both PAR1 and PAR2 signaling pathways and facilitates tumor 
growth (Mize et al., 2008; Ramsay et al., 2008). In addition, KLK6 was shown to 
stimulate cell proliferation and to reduce apoptosis in non-small lung cancer, through 
modulating the transactivation mechanism of PAR2-dependent epidermal growth factor 
receptor (EGFR) (Michel et al., 2014). 
Besides, accumulating evidence suggests a proliferative effect of KLKs in regulation 
of the hormone-associated signaling pathway. In prostate cancer, KLK2 (Shang et al., 
2014) and KLK3 (Niu et al., 2008) were reported to induce androgen receptor (AR) 
activation to facilitate cell proliferation. Also, enhanced expression of KLK4 (Lai et al., 
2014) and KLK14 (Lose et al., 2012) could modulate AR activation, via cleaving sex 
hormone-binding globulin, to promote prostate cancer growth.  
Moreover, KLKs may affect tumorigenesis by modulating activity and bioavailability 
of growth factors, which are essential for tumor progression. KLK1-5, KLK11, and 
KLK14 were reported to directly degrade insulin-like growth factor binding proteins 
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(IGFBPs), thus accelerating the release of insulin-like growth factor (IGF) and 
increasing the availability of IGF and the interaction with IGFBPs (Michael et al., 2006; 
Samani et al., 2007; Sano et al., 2007). This process reduces the anti-apoptotic effects 
of IGFs on tumor cells and the tumor suppression activity of IGFBPs, thereby resulting 
in tumor proliferation. Additionally, bioavailability of growth factors is modulated by 
KLKs through cleavage of the extracellular matrix (ECM) proteins, which are involved 
in sequestration of growth factors, such as fibroblast growth factor (FGF), epidermal 
growth factor (EGF), and transforming growth factor-beta (TGF-ß) (Lawrence et al., 
2010). Furthermore, some members of the KLK family, e.g. KLK4 and KLK5, can 
indirectly activate the hepatocyte growth factor/scatter factor (HGF/SF) pathway, a 
growth factor-associated signaling pathway, effecting cancer progression (Mukai et al., 
2008, 2015). 
Nevertheless, it has been reported that several KLKs have a tumor suppressive effect in 
carcinomas, e.g. elevated expression of KLK4 decreases proliferation in the prostate 
cancer cells (Veveris-Lowe et al., 2005). Besides, in vivo and in vitro studies have 
demonstrated that KLK10 inhibits cell proliferation in different cancer types, such as 
prostate (White et al., 2012), ovarian (White et al., 2010) and tongue cancer (Zheng et 
al., 2012).   
1.4.2 Roles of KLKs in tumor migration and invasion 
KLKs have been reported to be implicated in cell migration and invasion in 
malignancies, including lung (Chou et al., 2011), breast (Pampalakis et al., 2009), colon 
(Kim et al., 2011), pancreatic (Ramani et al., 2008), ovarian (Dong et al., 2013) and 
prostate (Mo et al., 2010) cancer. This might be due to the fact that KLKs mediate 
degradation of ECM barriers, which is essential for the dissemination of cancer cells 
(Kryza et al., 2016). Indeed, increasing evidence suggests that KLKs are able to degrade 
the major components of ECM, including fibronectin, vitronectin, collagens, and 
laminin (Lawrence et al., 2010). For example, elevated KLK13 expression in lung 
cancer induces laminin degradation and N-cadherin expression, thus facilitating tumor 
cell motility and metastasis (Chou et al., 2011). Besides, in the colon cancer cell line 
Caco2, KLK6 was shown to contribute to KRAS-dependent invasion and migration 
through laminin and the basement membrane-like substrate Matrigel (Henkhaus et al., 
2008).  
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Moreover, KLKs are involved in cell migration and invasion also via the proteolytic 
processing of cell adhesion and cell-cell cohesion proteins, such as E-cadherin, 
corneodesmosin, desmocollin, and desmoglein 1/2 (Lawrence et al., 2010). In prostate 
cancer cells, KLK3 and KLK4 have been demonstrated to decrease expression of the 
tumor suppressor E-cadherin, thus promoting tumor cell aggressiveness and 
invasiveness (Veveris-Lowe et al., 2005; Canel et al., 2013). Additionally, KLKs have 
been shown to regulate the process of epithelial-to-mesenchymal transition (EMT), 
where epithelial cells transform into mesenchymal-like cells, stimulating cell motility 
(Lawrence et al., 2007). KLK7 has been observed to promote the EMT-like phenotype 
in prostate tumor cells, as evidenced by the upregulation of the mesenchymal marker 
vimentin (Mo et al., 2010). Last but not least, KLKs may indirectly influence the 
migratory and invasive potential of cancer cells by modulating other molecular 
signaling pathways, such as PARs (Gao et al., 2010), MMPs (Ashby et al., 2010) and 
uPA-uPAR system (Beaufort et al., 2006). Inhibition of KLK14 by small interfering 
RNA (siRNA) in ovarian cancer cells was shown to suppress cell growth and invasion 
through down-regulating MMP2 expression and up-regulating the expression of 
caspase 9 and cleaved caspase 3 (Zhang et al., 2012).  
On the contrary, several KLKs have been shown to inhibit migration and invasion of 
tumor cells. Unlike in lung cancer, overexpression of KLK13 in oral squamous cell 
carcinoma cells was suggested as a tumor suppressor, reducing cell invasive potential 
and inducing the expression of adhesion molecules (Ishige et al., 2014). Also, 
overexpression of KLK8 was found to suppress cell proliferation and invasion in the 
lung adenocarcinoma cell line CL1-5, which might due to cleavage of fibronectin by 
KLK8, which can inhibit tumor cell motility by retarding actin polymerization (Sher et 
al., 2006).  
1.4.3 Roles of KLKs in tumor chemo-resistance  
A growing number of evidence indicates that KLKs might influence the efficacy of 
chemotherapies. In the ovarian cancer cell lines OVCA432 and SKOV-3, KLK4 
overexpression was associated with paclitaxel resistance by inducing the formation of 
multicellular aggregates (MCA), which could stimulate cell survival and 
chemoresistance (Dong et al., 2013). This effect was inhibited by KLK4-blocking 
antibodies or the selective active site KLK4 sunflower trypsin inhibitor (SFTI-FCQR) 
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(Dong et al., 2013). Furthermore, KLK7 has been reported to be associated with 
resistance to paclitaxel and tumor metastasis via enhancing the MCA formation and 
α5/β1integrin–dependent cell adhesion in ovarian cancer cells (Dong et al., 2010). 
Moreover, combined overexpression of KLK4-7 increased the insensitivity to 
paclitaxel in ovarian cancer cells by reducing the expression of α5β1/αvβ3 integrins 
(Loessner et al., 2012). Accordingly, this effect was shown to be abrogated via 
inhibition of KLK4-7 or MAPK in a spheroid-based animal model (Loessner et al., 
2013). Besides, modulation of transforming growth factor-β (TGF-β) in cycling rates 
and/or tumor microenvironments was found to be responsible for tumor heterogeneity 
and ultimately affect chemoresistance in squamous cell cancer stem cells (Oshimori et 
al., 2015). Furthermore, inhibition of TGF-β can promote chemotherapy action against 
TNBC (Bhola et al., 2013). This may explain that the overexpression of KLK4-7 in 
ovarian cancer cells promotes resistance to paclitaxel and invasion in a xenograft model 
by stimulating the expression of TGF-β (Shahinian et al., 2014).  
Conversely, some studies have suggested that overexpression of KLKs is potentially 
modulated by chemotherapeutic agents in tumor cells. For example, in prostate cancer 
cells, KLK5 mRNA expression levels were found to be up-regulated after treatment 
with etoposide, doxorubicin, and carboplatin, while KLK11 mRNA expression was 
increased following chemotherapy with mitoxantrone (Thomadaki et al., 2009). In BT-
20 breast cancer cells, KLK4 and KLK5 mRNA expression levels were shown to be 
decreased after treatment with epirubicin, docetaxel, and methotrexate, while KLK14 
mRNA expression was increased in epirubicin- and reduced in methotrexate-treated 
cells (Papachristopoulou et al., 2013). 
1.4.4 Roles of KLKs in tumor angiogenesis 
Angiogenesis, the growth of new blood vessels in tissues, is considered as an important 
hallmark of neoplasm, contributing to tumor growth, invasion and distant metastasis 
(Avgeris et al., 2012). KLKs promote key regulatory mechanisms in this process 
directly via diminishing ECM proteins or indirectly via activating uPA- and MMPs-
related cascades in the tumor microenvironment (Avgeris et al., 2012). Overexpression 
of KLK1 in endothelial progenitor cells was found to improve the secretion of vascular 
endothelial growth factor (VEGF) and to enhance neo-angiogenesis (Kryza et al., 2016). 
Furthermore, exogenous recombinant KLK1 was shown to induce invasive and 
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proangiogenic activities of proangiogenic cells by kinin receptors B2 (B2R)- and 
MMP2- mediated mechanisms (Spinetti et al., 2011), further suggesting an important 
role of KLK1 in angiogenesis. Moreover, KLK3 has been observed to stimulate 
angiogenesis through activating the proangiogenic factor TGFβ2 (Dallas et al., 2005). 
Besides, KLK12 was reported to enhance cancer cell proliferation and pro-angiogenic 
activity by indirectly modulating several growth factors, such as the bone morphogenic 
protein (BMP) 2, TGFβ and VEGF (Guillon-Munos et al., 2011).  
Nevertheless, some members of the KLK family, including KLK3 (Mattsson et al., 
2009), KLK5 (Michael et al., 2005), KLK6 (Bayés et al., 2004), and KLK13 
(Sotiropoulou et al., 2003), have been demonstrated to inhibit angiogenesis. These four 
KLKs were found to exert an anti-angiogenic effect through releasing angiostatin-like 
fragments from plasminogen, which potentially inhibit endothelial cell proliferation 
and angiogenesis (Avgeris et al., 2012; Kryza et al., 2016).  
1.5 Kallikrein-related peptidases as biomarkers in ovarian and breast cancer 
Regarding the impact on tumorigenicity, it is speculated that KLKs may be utilized as 
biomarkers for diagnosis and prognosis in carcinomas. KLKs have been reported to be 
aberrantly expressed in nearly all human solid tumors, especially in hormone-related 
cancers, including prostate, testicular, ovarian, and breast cancer (Tan et al., 2006; 
Avgeris et al., 2012; Schmitt et al., 2013; Lai et al., 2014). Expression and clinical 
relevance of KLKs in ovarian and breast cancer are summarized in Table 3 and Table 
4.  
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Table 3. Expression and clinical relevance of KLKs in ovarian cancer 
KLK Expression/ Source 
Clinical relevance 
References 
Favorable Unfavorable 
4 ↑ mRNA and protein in tissue  PFS; OS 
Davidson et al., 2005; 
Obiezu et al., 2001 
5 
↑ mRNA in tissue 
↑ protein in serum 
and ascites fluid  
PFS; OS PFS; OS 
Diamandis et al., 2003; 
Dorn et al., 2011; 
Dorn et al., 2016 
Kim et al., 2001;  
Oikonomopoulou et al., 2008  
6 
↑ mRNA and protein 
in tissue 
↑ protein in serum 
 PFS; OS Ahmed et al., 2016 Diamandis et al., 2003;  
Shan et al., 2007 
7 ↑ mRNA in tissue PFS; OS PFS; OS 
Dorn et al., 2014; 
Dorn et al., 2015; 
Kyriakopoulou et al., 2003;  
Shan et al., 2006;  
Psyrri et al., 2008 
8 ↑ mRNA in tissue ↑ protein in serum  PFS; OS PFS 
Magklara et al., 2001;  
Kishi et al., 2003;  
Kountourakis et al., 2009 
9 ND PFS; OS  Yousef et al., 2001 
10 ↑ protein in tissue ↑ protein in serum PFS; OS PFS; OS 
Dorn et al., 2007; 
Luo et al., 2001; 
Luo et al., 2003;  
Zheng et al., 2007;  
Oikonomopoulou et al., 2008 
11 ↑ protein in tissue ↑ protein in serum PFS; OS PFS; OS 
Borgoño et al., 2003;  
Geng et al., 2017 
Shigemasa et al., 2004;  
Zheng et al., 2007;  
Oikonomopoulou et al., 2008 
12 ND    
13 ↑ protein in tissue PFS; OS PFS 
Dorn et al., 2007; 
Scorilas et al., 2004;  
Zheng et al., 2007;  
White et al., 2009 
14 
↑ mRNA in tissue 
↑ protein in serum 
↓ protein in tissue 
PFS; OS  Dettmar et al., 2018; Yousef et al., 2003 
 
15 ↑ mRNA in tissue OS PFS; OS Geng et al., 2017; Yousef et al., 2003 
↑ increase; ↓ decrease; ND: not determined; OS: overall survival; PFS: progression-free 
survival. 
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Table 4. Expression and clinical relevance of KLKs in breast cancer 
KLK Expression/ Source Clinical relevance Reference Favorable Unfavorable 
3 ↑ in breast cell lines ↓ Protein in tissue OS; DFS  
Black and Diamandis, 2000; 
Yousef et al., 1999; 
Yu et al., 1998 
4 ↑ mRNA and protein in tissue  DFS 
Mangé et al., 2008; 
Yang et al., 2017 
5 
↓ mRNA in tissue 
↑ mRNA in tissue 
↑ protein in serum 
 OS; DFS 
Li et al., 2009; 
Yousef et al., 2002; 
Yousef et al., 2003; 
Yousef et al., 2004 
6 ↓ mRNA in tissue ND ND Yousef et al., 2004 
7 ↓ mRNA in tissue DFS OS; DFS 
Holzscheiter et al., 2006;  
Li et al., 2009; 
Talieri et al., 2004 
8 ↓ mRNA in tissue  DFS Michaelidou et al., 2015; Yousef et al., 2004 
9 ND OS; DFS  Yousef et al., 2003 
10 
↓ mRNA in tissue 
↑ mRNA in tissue 
↑ protein in serum 
↑ DNA methylation 
OS OS; DFS 
Dhar et al., 2001;  
Ewan et al., 2007;  
Kioulafa et al., 2009;  
Luo et al., 2002;  
Yousef et al., 2004;  
Wang et al., 2016 
11 ↓ mRNA in tissue ND ND Yousef et al., 2004 
12 
↓ mRNA in tissue 
↑ in breast cancer cell 
lines 
DFS; OS  
Papachristopoulou et al., 2018; 
Talieri et al., 2012; 
Yousef et al., 2000 
13 ↓ mRNA in tissue OS; DFS  Chang et al., 2002; Yousef et al., 2000 
14 
↓ mRNA in tissue 
↑ mRNA in tissue 
↑ protein in serum  
 OS; DFS 
Borgoño et al., 2003;  
Papachristopoulou et al., 2011; 
Yousef et al., 2001; 
Yousef et al., 2002;  
15 ND OS; DFS  Yousef et al., 2002 
↑ increase; ↓ decrease; ND: not determined; OS: overall survival; DFS: disease-free survival. 
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In ovarian cancer (Table 3), many members of the KLK family have been shown to be 
up-regulated. KLK4-8, KLK14, and KLK15 mRNA expression levels are elevated in 
ovarian cancerous cohorts. Enhanced protein levels of KLK4-8, KLK10-11, KLK13, 
and KLK15 have also been observed in ovarian cancer tissues, compared to healthy and 
benign tissues. In breast cancer (Table 4), mRNA expression of KLK5-8 and KLK10-
13 was reported to be decreased, compared with normal breast tissues. Additionally, 
KLK4 was found to be overexpressed both at the mRNA and protein levels in breast 
malignant tissues (Mangé et al., 2008; Yang et al., 2017). These findings further suggest 
that KLKs might serve as biomarkers for screening and/or diagnosis in ovarian and 
breast cancer. However, contradictory results have been published for several KLKs. In 
ovarian cancer, KLK14 was up-regulated in tumor tissues (Dettmar et al., 2018), while 
it was downregulated in the serum of ovarian cancer patients (Yousef et al., 2003). 
Similarly, in breast cancer, KLK5 (Li et al., 2009), KLK10 (Dhar et al., 2001), and 
KLK14 (Yousef et al., 2001) were decreased in tumor tissues, whereas they were 
enhanced in the serum of breast cancer patients (Yousef et al., 2003; Ewan et al., 2007; 
Borgoño et al., 2003). These discrepancies may be due to the fact that glandular 
destruction and angiogenesis potentially promote the release of KLK protein into serum 
during tumorigenesis. 
Numerous previous studies have determined the value of KLKs as prognostic and/or 
predictive biomarkers in ovarian and breast cancer. In ovarian cancer (Table 3), KLK4-
7 and KLK10 overexpression levels are associated with unfavorable outcome, while 
elevated expression of KLK8-9, KLK11, and KLK13-14 represent favorable predictive 
biomarkers. In breast cancer (Table 4), increased expression of KLK4-5, KLK8, 
KLK10, and KLK14 indicate an unfavorable prognosis, whereas up-regulation of 
KLK3, KLK9, KLK12-13, and KLK15 imply a favorable prognosis. Interestingly, 
however, there are controversial observations for several KLKs with regard to 
prognosis in ovarian and breast cancer. Dorn et al. (2016) suggested that overexpression 
of KLK5 by stromal cells, not tumor cells, was correlated with prolonged progression-
free survival (PFS) and overall survival (OS) in ovarian cancer, in contrast to the other 
studies indicated that elevated KLK5 expression was associated with shortened PFS 
and OS (Kim et al., 2001; Diamandis et al., 2003; Oikonomopoulou et al., 2008; Dorn 
et al., 2011). Also, in most cases, elevated KLK7 (Kyriakopoulou et al., 2003; Shan et 
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al., 2006; Psyrri et al., 2008; Dorn et al., 2015) and KLK10 (Luo et al., 2001; Zheng et 
al., 2007) levels were described as unfavorable markers in ovarian cancer, while two 
publications showed that ovarian cancer patients with positive expression of KLK7 
(Dorn et al., 2014) and KLK10 (Dorn et al., 2007) exhibited a favorable outcome. 
Similar observations have also been revealed for KLK8, KLK11, KLK13, and KLK15 
in ovarian cancer (Table 3) and KLK7 as well as KLK10 in breast cancer (Table 4). 
These conflicting findings can possibly be explained, on one hand, by different methods 
which were applied for detection and analysis in these studies, such as RT-PCR, ELISA 
and immunohistochemistry; on the other hand, in most of these studies rather 
heterogeneous patient cohorts were investigated, including distinct clinical stages, 
low/high grade tumors, and various subtypes of ovarian and breast cancer. The diverse 
expression patterns of KLKs in low versus high grade tumors and distinct subtypes may 
certainly result in erroneous conclusions. Therefore, the present study only enrolled 
patients with advanced high-grade serous ovarian cancer (HGSOC, FIGO stage III/IV) 
and triple-negative breast cancer (TNBC) to investigate the impact of KLKs on 
prognosis. 
1.6 Tumor biological roles of KLK4, KLK5, KLK7, and KLK12  
1.6.1 Kallikrein-related peptidase 4  
KLK4，also known as prostase/KLK-L1, is located immediately downstream of KLK2 
and upstream of KLK5 on chromosome 19q13.3–19q13.4 (Stephenson et al., 1999; 
Yousef et al., 1999). Two major alternative KLK4 transcripts have been reported, 
including the full-length KLK4-254 transcript and the exon 1-deleted KLK4-205 
transcript, both proteolytically encoding active serine proteases (Dong et al., 2005; 
Kurlender et al., 2005). Besides, several KLK4 transcripts with splice variations 
between exons 2 and 5 were observed, exhibiting a frame-shift in the coding region and 
producing truncated proteins, which do not have the essential serine and/or aspartic acid 
residues of the catalytic triad (Obiezu and Diamandis, 2000; Dong et al., 2001; 
Korkmaz et al., 2001; Myers and Clements, 2001). The full-length KLK4 transcript 
encodes a 254-amino acid pre-pro-serine protease, comprising an N-terminal signal 
peptide with 26 amino acids, followed the pro-peptide with 4 amino acids and the active 
protease domain with 224 amino acids (Nelson et al., 1999). The exon 1-deleted 
transcript (KLK4-205) encodes an N-terminally truncated 205-amino acid protein with 
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the absence of the signal peptide and the pro-peptide (Dong et al., 2005). The lack of 
exon 1 suggests that KLK4-205 has an intracellular localization and function, distinct 
from full-length KLK4 transcript and other KLKs, which are characterized by major 
extracellular functions (Korkmaz et al., 2001). Thus, KLK4, which is predominantly 
localized in the nucleus, is considered as a unique member of KLK family (Dong et al., 
2005).  
KLK4, a trypsin-like serine protease, shows an arginine/lysine-specific protease 
activity and is involved in physiological and pathological processes. It is well-known 
that KLK4 facilitates degradation of enamel matrix proteins during tooth maturation, 
exhibiting a key role in enamel mineralization (Hu et al., 2007; Lu et al., 2008; Opal et 
al., 2015). Furthermore, KLK4 is supposed to be an oncogene in various cancer types, 
including but not limited to oral, breast, ovarian, prostate, and colon carcinomas. 
Elevated KLK4 mRNA and protein expression levels were correlated with a higher 
probability of invasion and metastasis in oral squamous cell carcinomas, suggesting 
that KLK4 could serve as a potential therapeutic target (Papagerakis et al., 2015). 
Obiezu et al. (2001) observed that positive KLK4 mRNA expression is an independent 
unfavorable prognostic biomarker in patients with ovarian cancer. Consistently, Dong 
and co-workers (Dong et al., 2001, 2013) have observed the association of KLK4 
mRNA and antigen overexpression with advanced stage and paclitaxel resistance in 
serous ovarian cancer. Furthermore, KLK4 was found to be up-regulated in prostate 
carcinoma and to be modulated by steroid hormones in prostate and breast cancer cell 
lines (Nelson et al., 1999; Yousef et al., 1999). In breast cancerous tissues, KLK4 
mRNA levels were shown to be higher compared to normal and benign breast tissues 
(Papachristopoulou et al., 2009). Moreover, overexpression levels of KLK4 mRNA and 
protein showed a strong correlation with high grade and poor disease-free survival in 
this tumor entity (Mangé et al., 2008; Yang et al., 2017).  
1.6.2 Kallikrein-related peptidase 5 
KLK5/KLK-L2 was initially described as human stratum corneum tryptic enzyme 
(HSCTE), owing to its high expression in skin and potential effects on stratum corneum 
turnover and desquamation in the epidermis (Brattsand and Egelrud, 1999). Further 
studies indicated that KLK5 is telomeric to KLK4 and upstream of KLK6 mapping to 
chromosome 19q13.3-q13.4 (Yousef et al., 2000), encoding a 25 kDa trypsin-like serine 
 24 
 
protease (Brattsand and Egelrud, 1999; Yousef and Diamandis, 1999). In addition, 
KLK5 was found to structurally resemble KLK4 with approximately 54% amino acid 
sequence identity and present a high degree of homology with other KLKs (Kim et al., 
2001). KLK5 is produced as an inactive pre-pro-enzyme, comprising a 29-amino acid 
signal peptide, followed by a 37-amino acid activating pro-peptide and a 237-amino 
acid catalytic domain (Yousef and Diamandis, 1999). This inactive precursor can be 
activated by matriptase and KLK14 as well as by self-activation (Zhu et al., 2017). 
Moreover, KLK5 is supposed to be implicated in KLK activation cascades, thus 
activating numerous protease zymogens, including other pro-KLKs (De Veer et al., 
2016). 
KLK5 was originally found to be expressed in testis, skin, brain, and breast (Brattsand 
and Egelrud, 1999; Yousef and Diamandis, 1999), and was subsequently found also in 
the prostate (Michael et al., 2006) and kidney (Kriegel et al., 2012). KLK5 is 
predominantly responsible for skin desquamation by directly cleaving 
corneodesmosomal cadherins (Ekholm et al., 2000; Caubet et al., 2004). It also 
stimulates inflammation via induction of PAR2 signaling (Oikonomopoulou et al., 2006; 
Yamasaki et al., 2006; Stefansson et al., 2008) and is involved in pro-filaggrin 
processing (Sakabe et al., 2013). Furthermore, dysregulation of KLK5 might contribute 
to pathophysiological processes, due to its function of cleaving substrates or activating 
protease zymogens. For example, KLK5 has been reported to be involved in the 
pathogenesis of several skin diseases, such as Netherton syndrome (Yamasaki et al., 
2006; Furio et al., 2015) and atopic dermatitis (Komatsu et al., 2007; Kubo et al., 2012). 
Moreover, accumulating reports have suggested potential functions of KLK5 in human 
cancers, including oral (Jiang et al., 2011), breast (Yousef et al., 2002; Yang et al., 2015), 
urinary bladder (Shinoda et al., 2007), ovarian (Kim et al., 2001; Dorn et al., 2016), 
prostate (Yousef et al., 2002; Korbakis et al., 2009), and colorectal (Wu et al., 2016) 
malignancies. In ovarian cancer, KLK5 overexpression was shown to be positively 
associated with tumor grade and risks for relapse and death (Kim et al., 2001; 
Diamandis et al., 2003; Dorn et al., 2011). However, Dorn et al. (2016) have quantified 
KLK5 protein levels in 95 ovarian cancer patients, showing that the overexpression of 
KLK5 by stromal cells, but not by tumor cells, was significantly associated with 
prolonged DFS and OS. Similarly, in breast cancer, Papachristopoulou et al. (2013) has 
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revealed that KLK5 might serve as a tumor-suppressor. In contrast, most publications 
have demonstrated that overexpression of KLK5 is associated with estrogen receptor 
status, larger tumors, positive nodes, distal metastasis, and shortened DFS as well as 
OS (Yousef et al., 2002; Talieri et al., 2011; Yang et al., 2015). 
1.6.3 Kallikrein-related peptidase 7 
KLK7, also known as PRSS6 or the human stratum corneum chymotryptic enzyme 
(HSCCE), is located at the chromosomal locus 19q13.3–q13.4 between KLK6 
(centromere) and KLK8 (telomere) (Hansson et al., 1994; Yousef et al., 2000). The 
genomic structure of KLK7 comprises six exons, of which the first exon is non-coding, 
and five intervening introns highly conserved with other KLKs, encoding 253 amino 
acids pre-pro-enzyme (Yousef et al., 2000). Unlike most members of the KLK family, 
KLK7 is a chymotrypsin-like serine protease due to the absence of aspartate at position 
189 (Yousef et al., 2000; Debela et al., 2008). KLK7 expression has been identified to 
be up-regulated by estrogens and glucocorticoids in the breast cancer cell line BT-474 
(Yousef et al., 2000).  
Prior studies have reported that KLK7 is implicated in various pathophysiological 
processes in human organs, such as skin, lung, breast, prostate, and ovary (Shaw and 
Diamandis, 2007; Avgeris et al., 2010). KLK5, KLK7, and KLK14 are considered as 
major functional proteases in normal skin, where they exhibit crucial roles in the 
process of skin desquamation (Caubet et al., 2004). Furthermore, elevated expression 
of KLK5 and KLK7 have also been found in skin diseases like skin barrier disorders 
(Fischer and Meyer-Hoffert, 2013; Kalinska et al., 2016). Moreover, the tumor 
biological role of KLK7 has been evaluated individually or in panels in different types 
of cancer. Overexpression of KLK7 was observed in squamous (Zhao et al., 2011), 
cervical (Li et al., 2014; Raju et al., 2016), ovarian (Shan et al., 2006; Dong et al., 2010), 
pancreatic (Du JP et al., 2018) and colorectal (Walker et al., 2014) carcinomas, whereas 
down-regulation of KLK7 was shown in breast (Li et al., 2009; Ejaz et al., 2017), 
prostate (Xuan et al., 2008) and lung carcinomas (Planque et al., 2005). In ovarian 
cancer, elevated KLK7 expression was shown to be associated with chemoresistance 
and poor prognosis (Kyriakopoulou et al., 2003; Shan et al., 2006; Psyrri et al., 2008; 
Dong et al., 2010). However, Dorn et al. (2014) revealed that patients with high KLK7 
levels have a lower risk of relapse and cancer-related death than those with low KLK7 
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levels. Similarly, in breast cancer, most studies have indicated that KLK7 
overexpression was connected with advanced stage, distant metastasis, and shortened 
survival (Talieri et al., 2004; Prezas et al., 2006; Li et al., 2009). However, Holzscheiter 
et al. (2006) determined KLK7 mRNA expression in tumor tissue specimens from 155 
breast cancer patients and observed a favorable prognostic value of KLK7 mRNA 
expression in breast cancer. 
1.6.4 Kallikrein-related peptidase 12 
KLK12, originally known as KLK-L5, contains five coding exons and one 5’ 
untranslated exon (Yousef et al., 2000). KLK12 is structurally very similar to other 
KLKs, with the transcribed direction of being 21.3 kb telomeric to KLK13 and 1.5kb 
centromeric to KLK11 (Yousef et al., 2000). To date, four splice forms of KLK12 have 
been identified to produce secreted proteins, including the classical form and three 
alternative splice variants named KLK12sv1, KLK12sv2, and KLK12sv3 (Yousef et al., 
2000; Kurlender et al., 2005). KLK12 is synthesized as a pre-pro-enzyme, consisting 
of a 17-residue signal peptide, followed by a 21-residue cleavage site for activation and 
a 227-residue mature enzyme with a predicted molecular weight of 24.5 kDa (Memari 
et al., 2007). The secreted inactive pro-enzyme gains enzymatic activity via auto-
activation (Memari et al., 2007). Active KLK12 displays trypsin-like activity and thus 
cleaves peptide bonds after arginine and lysine (Memari et al., 2007). Furthermore, the 
activity of KLK12 was found to be quickly lost due to self-digestion or to be rapidly 
inhibited by interaction with Zn2+ as well as by covalent complex formation with α2-
antiplasmin (Memari et al., 2007). Besides, KLK12 has been identified to be up-
reglated by estrogen, androgen and progestin in LNCaP prostate cells and breast cancer 
cell line BT-474 (Yousef et al., 2000). 
KLK12 is widely expressed in human tissues, and particularly abundant in the human 
respiratory tract (Shaw and Diamandis, 2007; Hamilton and Whittaker, 2013). However, 
its physiological roles in the respiratory tract as well as other tissues are still ill-defined. 
Recent studies pointed to a potential effect of KLK12 on cell proliferation, angiogenesis, 
invasion, and migration, thereby influencing cancer progression (Kryza et al., 2014; Li 
and He, 2016; Kryza et al., 2018). In gastric cancer, KLK12 mRNA and protein 
expression levels were positively associated with lymph node status, histological type 
and TNM stages (Zhao et al., 2012). There, patients with elevated KLK12 expression 
 27 
 
levels have a worse 5-year survival rate in this tumor entity, compared to those with 
low KLK12 expression. Furthermore, Planque et al. (2008) have revealed that KLK12 
protein expression is down-regulated in non-small cell lung cancer (NSCLC). Here, 
KLK12 protein expression was positively correlated with tumor stage, smoking status, 
gender, and risk of NSCLC. In breast cancer, KLK12 mRNA levels were found to be 
decreased in tumor tissues and were increased by steroid hormones in breast cancer cell 
lines (Yousef et al., 2000). With regard to the splice variants of KLK12 in breast cancer, 
two studies have reported that KLK12sv3 expression was correlated with early stage, 
lower grade, and smaller tumor size (Talieri et al., 2012; Papachristopoulou et al., 2018). 
Moreover, breast cancer patients with elevated mRNA expression of KLK12sv3 
presented longer DFS and OS than those with lower KLK12sv3 mRNA levels, 
suggesting the potential prognostic value of KLK12 in this tumor entity. 
In summary, the evidence mentioned above highlights the tumor biological roles of 
KLK4, 5, 7, and 12 in various types of cancer, especially in ovarian and breast 
carcinomas. Of note, these four KLK genes may exert different effects on tumor 
progression depending on the tumor type or even subtype. Thus, the current project 
focuses on analyzing the mRNA expression and clinical relevance of KLK4, 5, 7, and 
12 in the well-defined homogenous cohorts of patients with advanced high-grade serous 
ovarian cancer and triple-negative breast cancer. 
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2 Aims of the study 
Numerous studies have demonstrated that KLK genes are dysregulated in various types 
of tumors and are implicated in cancer progression. Previous studies have focused on 
the diagnostic and prognostic values of KLKs in ovarian and breast malignancies in 
terms of refining clinical management for the individual cancer patient. However, 
advanced high-grade serous ovarian cancer and triple-negative breast cancer should 
receive more attention due to their aggressive behaviors and/or the lack of effective 
therapeutic targets. To date, KLK4, KLK5, KLK7, and KLK12 have been reported to 
play decisive roles in processes of ovarian and breast cancer. Nevertheless, these 
previously reported results were sometimes paradoxical. Therefore, the current study 
aimed at characterizing the mRNA expression patterns of KLK4, KLK5, KLK7 and 
KLK12 in homogenous patient cohorts with advanced high-grade ovarian cancer and 
triple-negative breast cancer, respectively. 
To achieve this, the following analyses were performed: 
1. Quantitative PCR assays to evaluate mRNA expression levels of KLK4, 5, 7 and 
12 in HGSOC and TNBC tissues. 
2. Correlation of KLK5 and KLK7 mRNA expression levels with their corresponding 
protein levels (available data from previous studies), respectively, in HGSOC. 
3. Correlation between continuous variables of KLKs in HGSOC and TNBC.  
4. Assessment of the statistical associations of mRNA expression levels of KLK4, 5, 
7 and 12 with clinicopathological parameters in patients with HGSOC and TNBC. 
5. Assessment of the statistical associations of mRNA expression levels of KLK4, 5, 
7 and 12 with clinical outcome in patients with HGSOC and TNBC. 
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3 Patients, Materials and methods 
3.1 Tissue collection and extraction 
3.1.1 Cohort 1: patients afflicted with advanced high-grade serous ovarian cancer  
A total of 139 tumor tissue specimens from patients afflicted with HGSOC, FIGO stage 
III/IV, were enrolled at the Department of Obstetrics and Gynecology, Klinikum Rechts 
der Isar, Technical University of Munich (TUM), Germany, between years 1990 and 
2013. All patients were treated with standard stage-related primary radical debulking 
surgery. Following surgery, all patients received systemic adjuvant treatment according 
to the consensus recommendations at that time, including platinum-based adjuvant 
chemotherapy. None of the cases received any neoadjuvant therapy previous to surgery. 
The clinical data of HGSOC patients are documented in Table 5.  
This study to assess the KLK expression in the collected ovarian cancer tissues was 
approved by the local Ethics Committee (Faculty of Medicine, TUM, Germany; project 
491/17 S). Written informed consent to utilize tissue specimens for research purposes 
was obtained from all patients. 
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Table 5. Clinical characteristics of advanced high-grade serous ovarian cancer 
patients in cohort 1 
Clinical variables n % 
All patients 139  
Median age 64  
(range) (33-88) years  
Median observation time of patients alive 29  
(range) (2-279) months  
Age   
≤ 60 years 58 41.7 
> 60 years 81 58.3 
Residual tumor mass   
0 mm 70 50.4 
> 0 mm 67 48.2 
no data 2 1.4 
Ascitic fluid volume   
≤ 500 ml 78 56.1 
> 500 ml 54 38.9 
no data 7 5.0 
FIGO stage   
III 108 77.7 
IV 31 22.3 
Disease recurrence   
yes 76 54.7 
no 33 23.7 
no data 30 21.6 
Alive recurrence   
yes 78 56.1 
no 47 33.8 
no data 14 10.1 
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3.1.2 Cohort 2: patients afflicted with triple-negative breast cancer 
The tumor tissue samples of 125 primary TNBC in this retrospective study were 
collected conducted between the year 1988 and 2012 at the Department of Obstetrics 
and Gynecology, Klinikum Rechts der Isar, TUM, Germany. All patients received 
standard surgical procedures, including breast conservation surgery and mastectomy. 
Following surgery, patients accepted adjuvant therapy based on consensus 
recommendations at that time, including anthracycline- or cyclophosphamide-based 
chemotherapy, endocrine therapy, and radiotherapy. The histomorphologic parameters 
and clinical data were summarized in Table 6.  
Tumor samples were routinely assessed for expression of HER2 and steroid hormone 
receptors (ER and PR) at the Department of Pathology before storage. Tumor specimens 
were classified as TNBC following the rules previous described (Yang et al., 2017): 
negative statues of ER and PR and lack or low levels of HER2 protein expression 
(immunohistochemically determined score 0 or 1+, or 2+ with negative fluorescence in 
situ hybridization [FISH] test for testing HER2 amplification).  
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Table 6. Clinical and pathological data of triple-negative breast cancer patients in 
cohort 2 
Clinical parameters n % 
All patients 125  
Median age     55   
(range) (30-96) years  
Median observation time of patients alive   79   
(range) (4-286) months  
Age   
≤ 60 years 68 54.4 
> 60 years 57 45.6 
Menopausal status   
pre-menopausal 41 32.8 
peri-menopausal 3 2.4 
post-menopausal 81 64.8 
Histological subtype   
invasive ductal 113 90.4 
medullary 2 1.6 
lobular 1 0.8 
other 9 7.2 
Tumor size   
pT1 34 27.2 
pT2 75 60.0 
pT3 7 5.6 
pT4 9 7.2 
Nodal status   
  pN0 71 56.8 
  pN1 40 32.0 
  pN2 10 8.0 
  pN3 4 3.2 
Metastasis   
yes 32 25.6 
no 93 74.4 
Histological grade   
II 12 9.6 
III 112 89.6 
IV 1 0.8 
Disease recurrence   
yes 54 43.2 
no 67 53.6 
unknown 4 3.2 
Adjuvant treatment   
chemotherapy 92 73.6 
endocrine therapy 20 16.0 
radiotherapy 94 75.2 
unknown 1 0.8 
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3.2 Cell culture  
OV-MZ-6, a human epithelial ovarian cancer cell line, was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM), which is supplemented with 10% fetal bovine 
serum (FBS), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
and 0.2% arginine/asparagine. The culture medium was replaced twice a week and cells 
were passaged after they reached a confluence of 80%. OV-MZ-6 cells grow adherently 
in a 75 cm2 culture flask (5% CO2 (v/v), 95% humidity, 37 °C). The reagents and 
materials were summarized in Table 7. 
 
Table 7. Reagents and materials used in the cell culture 
Cell culture flask (25 cm2, 75 cm2) Greiner Bio-one GmbH, Frickenhausen, Germany 
Cell culture microscope CK30, Olympus, Tokyo, Japan 
Centrifuge Rotina 48R, Andreas Hettich, Tuttlingen, Germany 
CO2 incubator Heraeus Function Line Serie 7000 
Cryogenic vials Thermo Fisher Scientific Inc., Rochester, NY, USA 
DMEM (Dulbecco's modified eagle’s 
Medium) 
#61965-026, Gibco, Invitrogen, Paisley, United 
Kingdom 
DMSO (dimethyl sulfoxide) #317275, Merck Chemicals, Darmstadt, Germany 
EDTA (ethylenediaminetetraacetic 
acid), 1% (w/v) 
#L2113, Biochrom GmbH, Berlin, Germany 
FBS (fetal bovine serum) #10270-106, Invitrogen, Carlsbad, USA 
Hemocytometer 0.1 mm, Neubauer improved chamber, Laboroptik 
Ltd, United Kingdom HEPES (4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid) 
#15630-080, Gibco, Invitrogen, Darmstadt, 
Germany 
Laminar flow cabinet (Hera Safe) M1199, Heraeus, Hanau, Germany 
L-arginine #A8094, Sigma, Munich, Germany 
L-asparagine #A7094, Sigma, Munich, Germany 
PBS (phosphate-buffered saline) #10010-015, Gibco, Invitrogen, Carlsbad, CA, USA 
Serological pipette Greiner Bio-one GmbH, Frickenhausen, Germany 
 
After thawing and properly passaging, adherent cells were used in the experiments. OV-
MZ-6 cells were detached using ethylenediaminetetraacetic acid/phosphate-buffered 
saline (EDTA/PBS; 1% w/v) and washed with phosphate-buffered saline (PBS). The 
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cell suspension was centrifuged at 1,300 rpm for 3 min and the supernatant was 
discarded. The steps of resuspension and centrifugation repeated again. Then, the OV-
MZ-6 cells were detached from the culture flask and 1x106 cells were rapidly 
resuspended in the freezing medium (FBS containing 10% dimethylsulfoxide [DMSO]) 
on ice. The cell suspension was transferred into cryogenic storage vials. Finally, the 
cells were frozen at -80 °C in cryogen storage vials for 24 h and transferred into liquid 
nitrogen at -196°C for storage.  
3.3 Quantitative polymerase chain reaction (qPCR) 
3.3.1 RNA isolation   
Human ovarian cancer OV-MZ-6 cells were employed, which had been stably 
transfected with pRcRSV-derived expression plasmids encoding the complete coding 
region of target KLKs (OV-KLK4, OV-KLK5, OV-KLK7, and OV-KLK12, 
respectively). The automated extraction and purification of total DNA and RNA from 
cell lines and tumor tissues was performed by using the QIAcube sample preparation 
device (Qiagen) and the All Prep DNA/RNA Universal kit (Qiagen). 
Tumor tissue specimens from both HGSOC and TNBC cases were immediately stored 
in liquid nitrogen after inspection by the pathologist until RNA extraction. Deep-frozen 
tumor tissues were obtained from the Tumor Bank of the Medical Faculty of TUM. The 
frozen tumor tissues were pulverized on ice and the still-frozen powder (10-20 μg) was 
immediately homogenized in 600 μl of RLT plus buffer (Qiagen) supplemented with 6 
μl 2-β-mercaptoethanol. Then, tumor lysates were centrifuged at full speed (3 min, RT) 
in QIAshredder spin columns (Qiagen). The supernatants were inserted into the 
QIAcube machine and the manufacturer’s recommendations were exactly followed. 
Concentration and purity of extracted RNA were quantified employing the NanoDrop 
2000c spectrophotometer and the NanoDrop 2000/2000c software (Thermo Fisher 
Scientific, Wilmington, USA). The RNA quality was assessed by determination of 
absorbance ratios at 260/280 nm and 260/230 nm. All RNA samples were stored at -
80°C until further use. 
3.3.2 Reverse transcription  
According to the manufacturer’s recommendations, reverse transcription of the isolated 
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mRNA was performed using the AMV First Strand cDNA Synthesis Kit (Invitrogen, 
Darmstadt, Germany). First, the annealing of primers was conducted in a PCR reaction 
tube as follows: 
Components Volume 
Isolated RNA 1000 ng (cell lines)  
  500 ng (tumor tissues)  
Random hexamer primers (50 ng/μl) 1 μl 
dNTP (10 mM) 2 μl 
DEPC-treated H2O x μl 
Total 12 μl 
The PCR reaction tubes were incubated in a thermal cycler (65 °C, 5 min) and then 
transferred on ice. Next, the following master reaction mix was added at 8 µl per well 
to the RNA/primers mixture: 
Components Volume 
cDNA synthesis buffer (5x) 4 μl 
DTT (0.1 M) 1 μl 
RNase out (40 U/μl) 1 μl 
Cloned AMV RT (15 U/μl) 0.9 μl 
DEPC-treated H2O 1.1 μl 
Then, the reaction tubes were transferred to a thermal cycler (Qiagen) with the 
following PCR program: 
Steps Temperature Time 
1 25 °C 10 min 
2 50 °C 50 min 
3 85 °C 5 min 
The resulting cDNA from frozen tumor tissues was diluted with RNase-free water 
resulting in a final cDNA concentration of 5 ng/μl, while the cDNA from cell lines was 
diluted to 10 ng/μl prepared for dilution series and calibrators. All cDNA samples were 
stored at -20°C until further use. 
3.3.3 qPCR analysis using Universal ProbeLibray probes 
Universal ProbeLibray probes (Roche) were employed for the quantitative polymerase 
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chain reaction (qPCR) method. These probes are short hydrolysis probes (8-9 
nucleotides), which are attached by a reporter with fluorescein (FAM) at the 5' end and 
by a dark quencher dye at the 3' end. The fluorogenic probes were able to target specific 
genes and the reporter dye was cleaved by the DNA polymerase, emitting its 
characteristic fluoresce. Hypoxanthine-Guanine Phosphoribosyl transferase 1 (HPRT1) 
was used as the reference gene, suitable for the assessment of biomarkers in ovarian 
and breast cancer (de Kok et al., 2005). 
For KLK5 and HPRT1, assays have been established in-house using the ProbeFinder 
software (https://lifescience.roche.com/products/universal-probe-library) and the 
Universal ProbeLibrary (Roche, Penzberg, Germany). The gene-specific primers were 
shown in Table 8. 
 
Table 8. Gene-specific primers of KLK5 and HPRT1 
 KLK5 HPRT1 
Transcript variants  NM_001077491.1 NM_001077492.1 
NM_012427.4 
NM_000194 
Primers 
(position) 
Forward 
5’-
AAGGCCCAACCAGCTCTACT-
3’ 
(476-495, 408-427, 611-630) 
5’-
TGACCTTGATTTATTTTGCATACC-
3’ 
(218-241) 
Reverse 
5’-
CCGAGACGGACTCTGAAAAC-
3’ 
(555-574, 487-506, 690-709) 
5’- 
CGAGCAAGACGTTCAGTCCT- 
3’  
(300-319) 
Probe  
(amplicon size) 
5’- 
FAM-GCAGGAAG- 
3’-dark quencher 
(99 bp) 
5’- 
FAM-GCTGAGGA- 
3’-dark quencher 
(102 bp) 
 
The assay detects all the major transcript variants of KLK5 and HPRT1, respectively, 
encoding full-length proteins. 
Regarding to KLK4, KLK7 and KLK12, assays were optimized to apply the 
Biosystems TaqMan gene expression assays from ThermoFisher, which consist of a pair 
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of unlabeled PCR primers and a TaqMan probe with a FAM dye label at the 5 'end and 
a minor groove binder (MGB) as well as a non-fluorescent quencher (NFQ) at the 3' 
end. The specific assays were summarized in Table 9. 
Table 9. Gene-specific assays of KLK4, KLK7, and KLK12 
KLK Transcript variants Assay ID amplicon size 
KLK4 NM_004917.4 
   NM_001302961.1 
Hs05041835_s1 120 bp 
KLK7 
NM_005046.3 
NM_139277.2 
   NM_001207053.1 
   NM_001243126.1 
Hs00192503_m1 70 bp 
KLK12 NM_019598.2 NM_145894.1 
NM_145895.1 
Hs00377603_m1 108 bp 
 
The assays detect all the major transcript variants of KLK4, KLK7, and KLK12, 
respectively, encoding full-length proteins. 
The experimental reaction mixture was prepared as shown in Tables 10 and 11. All 
qPCR reactions were conducted in triplicates (input: 15 ng/well for clinical samples 
and 30 ng/well for cell lines). cDNA from OV-MZ-6 cells overexpressing the target 
KLKs was used as the calibrator and positive control. Negative controls consisted of 
no-template control (water as substrate), genomic DNA (OV-MZ-6 cells), and no-RT 
control (untranscribed RNA from cell line as substrate). 
 
Table 10. qPCR reaction mixture for KLK5 and HPRT1 
Components Volume 
2x Brilliant III qPCR master mix with low ROX 10 μl 
UPL Probe (10 μM) 0.4 μl 
Primer forward (20 μM)  0.4 μl 
Primer reverse (20 μM) 0.4 μl 
H2O 5.8 μl 
Total 17 μl 
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Table 11. qPCR reaction mixture for KLK4, KLK7, and KLK12 
Components Volume 
2x Brilliant III qPCR master mix with low ROX 10 μl 
2x TaqMan® Gene Expression Master Mix 1 μl 
H2O 6 μl 
Total 17 μl 
 
The reaction mixture was distributed to a 96-well qPCR reaction plate (Biozym, 
Hamburg, Germany) and 3 µl of cDNA was added to each reaction well. Then, the plate 
was centrifuged at 3,000 rpm for 3 min and transferred to the Agilent Mx3005P 
instrument (Agilent, Darmstadt, Germany) for qPCR analysis. The steps of qPCR 
cycling program were shown in Table 12. 
 
Table 12. qPCR cycling program  
Segment Cycles Parameter Temperature Time 
1 1 Polymerase Activation 95 °C 3 min 
2 40 
Denature 95 °C 15 sec 
Anneal/Extend 60 °C 1 min 
 
3.3.4 Standard dilution series 
Due to sample heterogeneity and variation in extraction/conversion efficiency, standard 
dilution series were utilized to estimate the efficiency of KLK assays. Efficiency 
validation was carried out using a two-fold dilution series with cDNA from positive 
control cell lines (OV-MZ-6 cells overexpressing the target KLKs). Five dilution steps 
(cDNA0-cDNA4, range from 30 ng to 1.875 ng) were performed to establish the 
standard dilution curves of the KLKs and HPRT. The 2-fold dilution series for each 
gene was analyzed by qPCR in three independent experiments. The cycle threshold (Ct) 
value for each dilution step (y-axis) was plotted against the logarithm of the 
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corresponding cDNA input (log input 1.477-0.273; x-axis). The slope of the standard 
dilution series was calculated based on a linear regression analysis and further used to 
determine the efficiency (E) by the following calculation formula: E = 10 (–1/slope).  The 
acceptable range of efficiency (E) is 95-100% for qPCR assay validation, with the E 
value between 1.6 and 2. A ΔE between KLK and HPRT1 was estimated for calculation 
of ΔE-related error margins.  
3.3.5 qPCR evaluation method 
Relative quantitation analyses for mRNA expression of target KLKs were performed 
using the comparative threshold cycle (2-ΔΔCt) method (Pfaffl, 2012): ΔCt = Ct (KLK) 
- Ct (HPRT1); ΔΔCt = ΔCt (tumor sample) – ΔCt (calibrator).  
All measurements are subject to error or uncertainty. Thus, the random errors in 
observable quantities are measured by estimating the error propagation. Relative error 
propagation (EP) was calculated for each step by the following formula (STDEV: 
standard deviation): 
EP (∆Ct) = ඨ(𝑆𝑇𝐷𝐸𝑉௄௅௄)ଶ + (𝑆𝑇𝐷𝐸𝑉ு௉ோ்ଵ)ଶ2  
EP (∆∆Ct) = ඨ(𝐸𝑃∆େ୲೟ೠ೘೚ೝ ೞೌ೘೛೗೐)ଶ + (𝐸𝑃∆େ୲೎ೌ೗೔್ೝೌ೟೚ೝ)ଶ2  
Absolute error propagation was calculated by the following formula (ln: natural 
logarithm): EP (absolute error) = ln 2 × 𝐸𝑃(∆∆Ct) × 2–୼୼େ୲. 
Accounting for the detection limitations and the variations of sample qualities, the 
following quality criteria were applied in the present project to exclude unassertive 
results (Ahmed et al., 2016): (1) the Ct value for HPRT was > 35; (2) the 2exp-∆∆Ct 
error progression% was > 30% even after repetition; (3) the % STDEV of the 2exp-
∆∆Ct for 2 valid runs was > 47.1%. Based on this, sample numbers in statistical 
analyses do not always add up to 139 for ovarian cancer and to 125 for breast cancer. 
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3.4 Antigen expression levels of KLK5 and KLK7 in advanced high-grade serous 
ovarian cancer patients  
The KLK5 (Dorn et al., 2016) and KLK7 (Dorn et al., 2014) antigen levels of 46 of the 
139 cases of the present patient cohort 1 have been determined by an 
immunofluorometric assay (ELISA) in previous studies. The ELISA determinations 
and the qPCR analyses of the present project were performed with independent tissue 
samples of the same patient. 
3.5 Statistical analyses 
The association of KLK mRNA expression levels with clinical parameters of patients 
was analyzed using the Chi-square test. Associations of tumor biological factors and 
clinical survival were calculated by univariate and multivariate proportional hazard 
regression analyses and expressed as hazard ratio (HR) as well as its 95% confidence 
interval (95% CI). Survival curves were plotted according to Kaplan-Meier survival 
analysis, using the log-rank test to compare group differences of survival functions. The 
database from The Cancer Genome Atlas (TCGA) was applied to validate in silico the 
prognostic power of KLKs in HGSOC (not available for TNBC). 
The Mann-Whitney U test and Spearman rank correlation (rs) were utilized to assess 
the correlations between continuous variables of KLKs. The Mann–Whitney U test and 
Spearman rank correlation were also applied to analyze the relationship of KLK5 and 
KLK7 mRNA expression levels with their corresponding protein expression levels, 
respectively. Box plots were drawn to indicate differences. 
All calculations were performed employing the SPSS statistical analysis software 
(version 20.0; SPSS Inc., Chicago, IL, USA). P-values ≤ 0.05 were considered 
statistically significant. 
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4 Results 
4.1 KLK mRNA expression determined by qPCR in advanced high-grade serous 
ovarian cancer (cohort 1) 
4.1.1 Establishment of quantitative PCR assays for KLKs 
In an ideal qPCR assay, the amplification efficiency is supposed to be 100%, 
corresponding to an E value of 2. Actually, the qPCR efficiency has a wide dynamic 
range from 95% to 100%, with corresponding E values from 1.6 to 2 (Ruijter et al., 
2013). Thus, in the current study, the standard dilution series method was applied for 
evaluating the efficiencies of the target KLKs and the housekeeping gene HPRT1 
during qPCR assays (Bustin and Nolan, 2013). Based on this, 2-fold dilution series of 
cDNA from cell lines OVMZ6-KLK4, OVMZ6-KLK5, OVMZ6-KLK7, and OVMZ6-
KLK12, which individually overexpressed the respective KLK, were generated to 
calculate the efficiencies for each assay, with five dilution steps (cDNA0-cDNA4: range 
from 30 ng to 1.875 ng). As shown in Figure 3, the Ct value for each dilution step (y-
axis) was plotted against the logarithm of the corresponding cDNA input (log input 
1.477-0.273; x-axis).  
Three independent experiments were performed for each dilution series. As exemplified 
by the KLK4 dilution curves in Figure 3A, the slopes of the lines for KLK4 (1st -3.23; 
2nd -3.42; 3rd -3.67) are parallel with those of the reference gene HPRT (1st -3.36; 2nd -
3.24; 3rd -3.40). Furthermore, the E values of KLK4 (EKLK4: 1st 2.0; 2nd 1.96; 3rd 1.89; 
Table 13) are also comparable with those of HPRT (EHPRT: 1st 1.98; 2nd 2.04; 3rd 1.97; 
Table 13). Similarly, the E values of KLK5, KLK7, and KLK12 are comparable to 
those of HPRT (Table 13). Therefore, efficiency correction was not required for 
normalization and the relative KLK mRNA expression was calculated using the 2-ΔΔCt 
method in the succeeding analyses (see chapter 3.3.5 for details).  
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Figure 3. Exemplary dilution series of cDNAs for detection of KLKs and HPRT by 
qPCR 
HPRT was used as the reference gene. Total RNA was isolated from OV-MZ-6 cell lines 
overexpressing KLK4, 5, 7, and 12, respectively, and reverse transcribed. Standard dilution 
series curves were plotted by 2-fold serial dilutions starting with 30 ng cDNA input (dots 
from left to right: cDNA4, cDNA3, cDNA2, cDNA1, cDNA0). Slopes: (A) KLK4 -3.32, 
HPRT -3.36; (B) KLK5 -3.34, HPRT -3.19; (C) KLK7 -3.37, HPRT -3.40; (D) KLK12 -3.43, 
HPRT -3.41. 
 
Table 13. Efficiency values of KLKs in three independent dilution series are 
comparable to those of HPRT 
Dilution series Efficiency values 
EKLK4/EHPRT EKLK5/EHPRT EKLK7/EHPRT EKLK12/EHPRT 
1st run 2.0/1.98 1.99/2.05 1.98/1.97 1.99/1.97 
2nd run 1.96/2.04 1.95/2.02 2.04/1.99 2.01/2.0 
3rd run 1.89/1.97 1.93/1.99 2.0/1.97 1.96/1.96 
 
To validate the qPCR assay, the relative KLK mRNA expression levels of cDNA1-4 
were calculated with normalization against HPRT (CtKLK-CtHPRT) and cDNA0 (CtcDNA-
CtcDNA0), as demonstrated in Figure 4. In the three independent repetitions, the standard 
deviations (SDs) of the relative KLK mRNA expression in cDNA1-4 were all lower 
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than 20%.  
 
Figure 4. Mean values and standard deviations of relative KLK mRNA expression in 
three independent qPCR dilution experiments 
Relative mRNA expression of KLK4 (A), KLK5 (B), KLK7 (C), and KLK12 (D) were 
calculated in cDNA1-4 with normalization against HPRT and cDNA0. Mean values of 
relative KLK mRNA expression were in close proximity and all SDs were lower than 20% 
in cDNA1-4. 
 
Next, three cDNA samples from ovarian cancer tissue were randomly collected for a 
pretest. For each clinical sample, triplicates were analyzed regarding the relative KLK 
mRNA expression in three independent assays. For KLK4, 5 and 7, all Ct values of 
HPRT and the 2-ΔΔCt error progression % met the inclusion criteria (see chapter 3.3.5 
qPCR evaluation method). Furthermore, all SDs of the relative KLKs mRNA 
expression levels in the three repetitions were less than 47.1% (Figure 5). Thus, based 
on our criteria, none of the three samples would have been excluded for subsequent 
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analyses, which also validated the stability of the established qPCR assays for KLK4, 
5, and 7. However, KLK12 mRNA expression was not detected in the three samples, 
even after repetitions. We further analyzed 32 ovarian cancer specimens and observed 
that KLK12 mRNA was not detected in these ovarian cancer tissues as well. Thus, in 
this ovarian cancer subgroup, expression of KLK12 mRNA seems to be very low, even 
absent. Therefore, subsequent quantification of KLK12 was not performed in the 
HGSOC cohort. 
 
Figure 5. Mean values and standard deviations of relative KLK mRNA expression in 
three ovarian cancer specimens   
In three separated qPCR experiments, standard deviations of relative mRNA expression of 
KLK4 (A), KLK5 (B), and KLK7 (C) were all less than 47.1% in three ovarian cancer 
specimens. KLK12 mRNA expression was not detected in the three ovarian cancer 
samples during the three repetitions. cDNA from OV-MZ-6 cell lines overexpressing 
KLK4, 5, 7, and 12, respectively, were used as calibrators. OVC: tumor tissues of ovarian 
cancer patients. 
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4.1.2 Determination of KLK mRNA expression by qPCR in advanced high-grade 
serous ovarian cancer  
The KLKs mRNA levels were determined in the well-defined homogeneous cohort 
including 139 patients with HGSOC, FIGO stage III/IV (for details see chapter 3.1; 
Gong et al., 2019a, 2019b). Relative KLK mRNA expression was calculated with 
normalization against HPRT and the calibrators. The relative KLK4 mRNA expression 
levels were in the range of 0 to 0.44 (median, 0.019). Thus, rather low KLK4 mRNA 
expression was observed in the majority of cases (Figure 6A). Based on the expression 
pattern, the median value (50th percentile) was defined as the cut-off point for KLK4 to 
categorize its mRNA expression levels into a low- and a high-expression group. 
Relative KLK5 mRNA expression levels ranged from 0 to 644.31 (median, 16.87), 
while relative KLK7 mRNA expression levels were in the range of 0 to 953.22 (median, 
79.25). Most ovarian cancer specimens displayed robust KLK5 as well as KLK7 
expression (Figure 6B, Figure 6C, respectively). Based on the expression patterns, 
KLK5 and KLK7 mRNA expression levels were both dichotomized by the cut-off point 
at the 67th percentile into a low-expressing group (tertiles 1+2) versus a high-expressing 
group (tertile 3).  
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Figure 6. Relative KLK mRNA expression in tumor tissues of patients afflicted with 
advanced high-grade serous ovarian cancer 
The cumulative histograms represent relative KLK mRNA expression levels. The majority 
of samples presented very low KLK4 mRNA expression, while most cases displayed robust 
mRNA expression levels of KLK5 and KLK7. For further analysis, we classified KLK4 (A) 
mRNA levels into a low- versus a high-expression group by the median (50th percentile), 
while both KLK5 (B) and KLK7 (C) mRNA levels were categorized into a low-expressing 
group (tertiles 1+2) versus a high-expressing group (tertile 3) by 67th percentile.  
 
Including available protein expression data of KLK5 and KLK7, previously determined 
by ELISA method from a partially-overlapping cohort (Dorn et al., 2014, 2016), the 
relationship of their mRNA expression with corresponding protein expression was 
evaluated (n=46). 
Spearman rank correlation analysis showed that KLK5 protein expression levels are 
significantly associated with its mRNA expression levels (rs=0.689, p<0.001). This 
finding was also investigated by box plot analysis (Figure 7A), where higher KLK5 
protein levels are present in the group with elevated KLK5 mRNA expression and vice 
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versa (Mann-Whitney test, p<0.001). Similarly, a strong positive correlation between 
KLK7 mRNA and protein levels was observed using Spearman rank correlation 
analysis (rs=0.663, p<0.001), which was further validated by box plot analysis (Mann-
Whitney test, p=0.007). As demonstrated in Figure 7B, high KLK7 protein levels are 
significantly associated with increased KLK7 mRNA expression.  
  
Figure 7. Correlation of KLK5 and KLK7 mRNA levels with their protein levels in 
tumor tissues of advanced high-grade serous ovarian cancer 
(A) Higher KLK5 protein levels are present in the KLK5 mRNA high expression group and 
vice versa (Mann-Whitney test, p<0.001). (B) High KLK7 protein levels are significantly 
associated with increased KLK7 mRNA expression (Mann-Whitney test, p=0.007). Relative 
KLK mRNA expression was determined by qPCR and protein levels were measured by 
ELISA. 
 
Moreover, Spearman correlation analysis was also performed among these KLKs. 
KLK5 mRNA levels are significantly correlated with KLK7 mRNA levels (rs=0.568, 
p<0.001); also, a similar association was observed between KLK5 and KLK7 protein 
expression levels (rs=0.805, p<0.001). This relationship was further evident in box plot 
analysis, where KLK7 mRNA levels are significantly higher in the KLK5 mRNA high 
group (Mann-Whitney test, p<0.001; Figure 8A), and, similarly, KLK7 antigen levels 
are elevated in the KLK5 antigen high group (Mann-Whitney test, p<0.001; Figure 8B). 
These results strongly suggested the coordinate expression of KLK5 with KLK7 in 
HGSOC. There is no obvious correlation among other KLKs in HGSOC (rs<0.2).  
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Figure 8. Correlation between KLK5 and KLK7 mRNA expression in tumor tissues of 
advanced high-grade serous ovarian cancer  
(A) Higher KLK7 mRNA levels were observed in the KLK5 mRNA high group (Mann-
Whitney test, p<0.001). (B) Higher KLK7 antigen levels were observed in the KLK5 antigen 
high group (Mann-Whitney test, p<0.001. Relative KLK mRNA expression was determined 
by qPCR and protein levels were measured by ELISA. 
 
4.1.3 Association of KLK mRNA expression with clinical parameters in advanced 
high-grade serous ovarian cancer  
The relationship of dichotomized KLK mRNA expression (low/high) with established 
clinical parameters, including age, residual tumor mass, and pre-operative ascites fluid 
volume, are summarized in Table 14. KLK4 mRNA levels correlated with age and pre-
operative ascites fluid volume (p=0.006, p=0.042, respectively). A significant 
association was also observed between KLK5 mRNA expression and residual tumor 
mass (p=0.041). As to KLK7, its mRNA levels did not display any association with the 
above mentioned clinical variables. 
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Table 14. Association between KLK mRNA expression and clinical parameters in 
patients with advanced high-grade serous ovarian cancer  
Clinical parameters 
KLK4a 
low/high 
KLK5a 
low/high 
KLK7a  
low/high 
Age p=0.006 p=0.476 p=0.564 
≤ 60 years 37/21 35/23 40/18 
> 60 years 32/48 53/27 56/25 
Residual tumor mass p=0.303 p=0.041 p=0.234 
0 mm 38/32 51/19 51/19 
> 0 mm 30/36 37/29 44/23 
Ascites fluid volume p=0.042 p=0.087 p=0.261 
≤ 500 ml 45/33 54/23 54/24 
> 500 ml 21/32 30/24 41/13 
a Chi-square test (cut-off point: KLK4 = 50th percentile, KLK5 = 67th percentile, KLK7 
= 67th percentile).  
Bold values indicate statistical significance (p≤0.05). 
 
4.1.4 Association of KLK mRNA expression and established clinical parameters 
with progression-free survival and overall survival in advanced high-grade serous 
ovarian cancer 
The prognostic values of KLK mRNA expression and clinical parameters for the patient 
outcome (PFS/OS) were estimated by univariate and multivariate Cox regression 
analyses. In univariate Cox regression analysis (Table 15, Table 16), residual tumor 
mass and ascites fluid volume are univariate predictors both for PFS and OS. Patients 
with residual tumor mass (>0 mm) have a significantly higher risk of disease relapse 
and cancer-related death, compared to the tumor-free cases. A larger ascites fluid 
volume (>500 ml) predicts worse PFS and OS. 
In HGSOC, KLK4 mRNA expression (Table 15) represents an unfavorable predictive 
factor for OS (HR: 2.28, 95%CI: 1.38-3.76, p=0.001), indicating an approximately two-
fold increased probability of cancer-related death in the KLK4 high-expressing group. 
However, no significant association was observed between KLK4 mRNA levels and 
PFS. Regarding KLK5 (Table 16), elevated mRNA levels are significantly associated 
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with shortened PFS (HR: 1.60, 95% CI: 1.01-2.55, p=0.047), but not with OS. Elevated 
KLK7 mRNA levels (Table 16) present an unfavorable prognostic value for PFS (HR: 
1.75, 95% CI: 1.07-2.84, p=0.025) and show a trend towards significance in case of OS 
(HR: 1.66, 95% CI: 0.99-2.79, p=0.055). 
 
Table 15. Univariate Cox regression analysis of KLK4 mRNA expression and clinical 
parameters with patient survival in advanced high-grade serous ovarian cancer  
Clinical parameters PFS OS 
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.627   0.348 
≤ 60 years 43 1  50 1  
> 60 years 65 1.12 (0.70-1.79)  76 1.27 (0.77-2.08)  
Residual tumor mass   <0.001   <0.001 
0 mm 59 1  64 1  
> 0 mm 49 2.53 (1.60-4.02)  60 3.76 (2.18-6.48)  
Ascites fluid volume   0.018   0.011 
≤ 500 ml 63 1  72 1  
> 500 ml 39 1.78 (1.10-2.87)  47 1.93 (1.16-3.18)  
KLK4 mRNAc   0.121   0.001 
low 55 1  62 1  
high 52 1.44 (0.91-2.78)  63 2.28 (1.38-3.76)  
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of univariate Cox regression analysis;  
c Dichotomized into low and high levels by the 50th percentile; 
Bold values indicate statistical significance (p≤0.05). 
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Table 16. Univariate Cox regression analysis of KLK5 and KLK7 mRNA expression 
and clinical parameters with patient survival in advanced high-grade serous ovarian 
cancer 
Clinical parameters PFS OS 
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.762   0.414 
≤ 60 years 43 1  49 1  
> 60 years 62 1.08 (0.67-1.72)  70 1.24 (0.74-2.06)  
Residual tumor mass   <0.001   <0.001 
0 mm 58 1  60 1  
> 0 mm 47 2.41 (1.53-3.90)  57 3.80 (2.17-6.65)  
Ascites fluid volume   0.019   0.005 
≤ 500 ml 61 1  66 1  
> 500 ml 38 1.79 (1.10-2.90)  46 2.10 (1.25-3.54)  
KLK5 mRNAc    0.047   0.269 
low 62 1  73 1  
high 42 1.60 (1.01-2.55)  45 1.33 (0.80-2.20)  
KLK7 mRNAd   0.025   0.055 
low 73 1  82 1  
high 32 1.75 (1.07-2.84)  37 1.66 (0.99-2.79)  
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of univariate Cox regression analysis;  
c Dichotomized into low and high levels by the 67th percentile; 
d Dichotomized into low and high levels by the 67th percentile; 
Bold values indicate statistical significance (p≤0.05); values in italics indicate a trend 
towards significance. 
 
Furthermore, the impact of KLKs on clinical outcome was validated by the respective 
Kaplan-Meier survival analysis. The patients in the KLK4 mRNA high group (Figure 
9) have a worse OS, compared to the low subgroup. KLK5 overexpression (Figure 10) 
as well as KLK7 overexpression (Figure 11) were significantly correlated with 
shortened PFS. 
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Figure 9. Kaplan–Meier survival analysis concerning KLK4 mRNA expression in 
patients with advanced high-grade serous ovarian cancer  
Patients with elevated KLK4 mRNA levels display a significantly worse OS (p=0.001, B) 
but not PFS (A), compared with those with low KLK4 mRNA levels. 
 
Figure 10. Kaplan–Meier survival analysis concerning KLK5 mRNA expression in 
patients with advanced high-grade serous ovarian cancer 
Patients with elevated KLK5 mRNA levels display a significantly shortened PFS (p=0.041, 
A) but not OS (B), compared with those with low KLK5 mRNA levels. 
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Figure 11. Kaplan–Meier survival analysis concerning KLK7 mRNA expression in 
patients with advanced high-grade serous ovarian cancer 
Patients with elevated KLK7 mRNA levels display a significantly worse PFS (p = 0.021, A) 
and show a trend towards significance in case of OS (B), compared with those with low 
KLK7 mRNA levels. 
  
Multivariate Cox regression analysis was performed to assess the independent 
prognostic value of the clinical parameters and KLK mRNA expression in HGSOC. 
First, a base model was established, consisting of the established clinical parameters 
age, residual tumor mass, and ascites fluid volume. Here, residual tumor mass is the 
only independent predictive marker for the outcome, while ascites fluid volume loses 
its prognostic value. Next, the KLKs were individually added to the base model, 
summarized in Table 17-19. When subjected to multivariate Cox regression analysis, 
KLK4 mRNA expression retains the unfavorable predictive power for OS (HR: 2.31, 
95% CI: 1.27-4.20, p=0.006; Table 17). KLK5 mRNA expression may have a trend 
towards significance for PFS (HR: 1.53, 95% CI: 0.93-2.51, p=0.095; Table 18). In 
case of KLK7 (Table 19), mRNA expression represents an unfavorable predictor for 
PFS (HR: 2.19, 95% CI: 1.23-3.89, p=0.007) and OS (HR: 1.94, 95% CI: 1.06-3.55, 
p=0.032). To sum up, KLK4 and KLK7 mRNA expression were demonstrated to be 
independent biomarkers for patient outcome in HGSOC. 
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Table 17. Multivariate Cox regression analysis of KLK4 mRNA expression and clinical 
parameters with patient survival in advanced high-grade serous ovarian cancer  
The biological marker KLK4 mRNA was added to the base model of clinical parameters, 
which included age, residual tumor mass, and ascites fluid volume. Significant p-values 
(p≤0.05) are indicated in bold. 
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of multivariable Cox regression analysis;  
c Dichotomized into low and high levels by 50th percentile. 
  
Clinical parameters PFS OS 
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.733   0.470 
≤ 60 years 41 1  47 1  
> 60 years 60 0.92 (0.56-1.51)  69 1.22 (0.72-2.07)  
Residual tumor mass   0.002   <0.001 
0 mm 58 1  63 1  
> 0 mm 43 2.36 (1.38-4.05)  53 3.58 (1.90-6.74)  
Ascites fluid volume   0.474   0.911 
≤ 500 ml 63 1  71 1  
> 500 ml 38 1.22 (0.71-2.10)  45 1.03 (0.58-1.86)  
KLK4 mRNAc   0.284   0.006 
low 52 1  58 1  
high 49 1.32(0.79-2.20)  58 2.31 (1.27-4.20)  
 55 
 
Table 18. Multivariate Cox regression analysis of KLK5 mRNA expression and clinical 
parameters with patient survival in advanced high-grade serous ovarian cancer 
The biological marker KLK4 mRNA was added to the base model of clinical parameters, 
which included age, residual tumor mass, and ascites fluid volume. Significant p-values 
(p≤0.05) are indicated in bold. 
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of multivariable Cox regression analysis;  
c Dichotomized into low (tertiles 1+2) and high (tertile 3) levels by 67th percentile. 
  
Clinical parameters PFS OS 
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.592   0.660 
≤ 60 years 41 1  46 1  
> 60 years 57 0.87 (0.53-1.44)  63 1.13 (0.65-1.96)  
Residual tumor mass   0.005   <0.001 
0 mm 57 1  59 1  
> 0 mm 41 2.20 (1.17-3.81)  50 3.29 (1.69-6.41)  
Ascites fluid volume   0.363   0.605 
≤ 500 ml 60 1  64 1  
> 500 ml 38 1.33 (0.76-2.31)  45 1.18 (0.64-1.91)  
KLK5 mRNAc   0.095   0.718 
low 59 1  69 1  
high 39 1.53 (0.93-2.51)  40 1.11 (0.64-1.91)  
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Table 19. Multivariate Cox regression analysis of KLK7 mRNA expression and clinical 
parameters with patient survival in advanced high-grade serous ovarian cancer  
The biological marker KLK4 mRNA was added to the base model of clinical parameters, 
which included age, residual tumor mass, and ascites fluid volume. Significant p-values 
(p≤0.05) are indicated in bold. 
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of multivariable Cox regression analysis;  
c Dichotomized into low (tertiles 1+2) and high (tertile 3) levels by 67th percentile. 
 
4.1.5 Validation of the association of KLK mRNA expression with patients survival 
in advanced high-grade serous ovarian cancer by in silico analysis using publicly 
available data 
To further estimate the association of KLK mRNA expression with patient outcome in 
HGSOC, the online biomarker assessment tool, Kaplan-Meier Plotter, was used to 
analyze the publicly available Affymetrix-based mRNA data of ovarian cancer patients 
from The Cancer Genome Atlas (Gyorffy et al., 2012). For this, patients with clinical 
characteristics of advanced stage (FIGO III+IV), high-grade (grade 3) and serous 
ovarian cancer, receiving platinum-based chemotherapy, with a follow-up of 5 years 
Clinical parameters PFS OS 
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.633   0.609 
≤ 60 years 41 1  46 1  
> 60 years 58 0.89 (0.54-1.46)  64 1.15 (0.67-1.99)  
Residual tumor mass   0.003   <0.001 
0 mm 57 1  59 1  
> 0 mm 42 2.26 (1.32-3.89)  51 3.42 (1.77-6.62)  
Ascites fluid volume   0.363   0.696 
≤ 500 ml 61 1  65 1  
> 500 ml 38 1.29 (0.75-2.23)  45 1.13 (0.61-2.09)  
KLK7 mRNAc   0.007   0.032 
low 72 1  80 1  
high 27 2.19 (1.23-3.89)  30 1.94 (1.06-3.55)  
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and dichotomized by the same cut-off point used in the present study, were selected to 
evaluate and plot the Kaplan–Meier survival curves. For KLK4 (Affymetrix probe ID: 
1555737_a_at), 249 cases for PFS and 252 cases for OS, respectively, were enrolled for 
Kaplan–Meier survival analysis, showing that elevated KLK4 mRNA expression is 
significantly linked with poor OS (p=0.047), but also with PFS (p=0.032) (Figure 12). 
In case of KLK5, 377 (PFS) and 398 (OS) patients could be enrolled to evaluate the 
predictive power of KLK5 (Affymetrix probe ID: 222242_s_at). Here, KLK5 
represents an unfavorable biomarker for PFS (p=0.027), but not for OS (Figure 13). In 
contrast to our finding, KLK7 mRNA (Affymetrix probe ID: 239381_at) did not 
contribute to the prediction of OS or PFS in the selected cohort consisting of 249 
patients for PFS and 252 patients for OS (Figure 14). 
 
Figure 12. Association of KLK4 mRNA expression with patient outcome in the publicly 
available Affymetrix microarray data set  
In this in silico analysis, 249 patients for PFS and 252 patients for OS were enrolled for 
Kaplan-Meier analysis. The Kaplan-Meier survival curves indicate that elevated KLK4 
mRNA expression (probe ID: 1555737_a_at) is significantly linked with poor PFS (p=0.032, 
A), but also for OS (p=0.047, B). 
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Figure 13. Association of KLK5 mRNA expression with patient outcome in the publicly 
available Affymetrix microarray data set  
377 patients (PFS) and 398 patients (OS) were selected to calculate the predictive power of 
KLK5 (probe ID: 222242_s_at). The Kaplan-Meier survival curves indicated that KLK5 
represents an unfavorable biomarker for PFS (p=0.027, A), but not for OS (B).  
 
Figure 14. Association of KLK7 mRNA expression with patient outcome in the publicly 
available Affymetrix microarray data set  
As to KLK7 (probe ID: 239381_at), 249 patients were analyzed for PFS (A) and 252 patients 
for OS (B). The Kaplan-Meier survival curves indicated that KLK7 mRNA did not 
contribute to the prediction of OS or PFS. 
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4.2 Assessment of KLK mRNA expression by qPCR in triple-negative breast 
cancer (cohort 2) 
4.2.1 KLK mRNA expression in tumor tissues of triple-negative breast cancer 
The mRNA levels of KLK4, KLK5, KLK7, and KLK12 were also quantified in primary 
tumor tissues from a well-defined breast cancer cohort, including 125 patients afflicted 
with TNBC, applying the newly established qPCR assay. The relative KLK4 mRNA 
expression levels ranged from 0 to 8.19 (median, 0.08); regarding KLK5, the relative 
mRNA expression was in the range of 0 to 1778.77 (median, 8.08); relative KLK7 
mRNA levels ranged from 0 to 302.33 (median, 4.44). In most of the TNBC specimens, 
KLK4 mRNA displayed a low expression, while robust KLK5 and KLK7 mRNA 
expression levels were observed. Based on the expression patterns, KLK4 mRNA 
expression levels (Figure 15A) were categorized into a low-expressing group (tertiles 
1+2) versus a high-expressing group (tertile 3) by 67th percentile, which was also the 
cut-off point used for KLK5 (Figure 15B) and KLK7 (Figure 15C). 
In case of KLK12, the relative mRNA expression levels ranged from 0 to 0.38 (median, 
0.00), whereby more than half of the cases (62/114, 54%) displayed a negative 
expression (Figure 15D). Based on this, KLK12 mRNA expression was categorized 
into a negative-expressing group (54%) versus a positive-expressing group (46%). 
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Figure 15. Relative KLK mRNA expression in tumor tissues of patients afflicted with 
triple-negative breast cancer 
Most of the cases in the TNBC cohort display low mRNA expression of KLK4 and KLK12, 
while KLK5 and KLK7 show robust mRNA expression patterns. Based on this, the relative 
mRNA expression levels of KLK4 (A), KLK5 (B) and KLK7 (C) were categorized into a 
low-expressing group (tertiles 1+2) versus a high-expressing group (tertile 3) by 67th 
percentile, whereas relative KLK12 mRNA expression (D) was classified into a negative-
expressing group (54%) versus a positive-expressing group (46%). 
 
Spearman correlation analysis was also performed among these KLKs. A strong 
correlation was observed between KLK5 mRNA expression and KLK7 mRNA 
expression (rs=0.735, p<0.001). This relationship was also evident in box plot analysis, 
where KLK7 mRNA levels are significantly higher in the KLK5 elevated group (Mann-
Whitney test, p<0.001; Figure 16), strongly suggesting the coordinate expression of 
KLK5 with KLK7 in TNBC. There is no obvious correlation among other KLKs in 
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TNBC (rs<0.2).  
 
Figure 16. Correlation between KLK5 and KLK7 mRNA expression in tumor tissues 
of triple-negative breast cancer  
KLK7 mRNA levels are significantly higher in the KLK5 elevated group (Mann-Whitney 
test, p<0.001), compared to the KLK5 low group. Relative KLK mRNA expression was 
determined by qPCR. 
 
4.2.2 Association of KLK mRNA expression with clinicopathological parameters 
in triple-negative breast cancer 
In the TNBC cohort, the association between KLK mRNA expression levels and the 
established clinicopathological parameters (age, lymph node status, tumor size, and 
histological grade) was estimated applying the Pearson Chi-square (χ²) test. As depicted 
in Table 20, histological grade is significantly associated with KLK4 mRNA expression 
levels (p=0.004). No other relationship between KLK mRNA expression and the 
mentioned clinicopathological parameters was observed in this tumor entity. 
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Table 20. Association between KLK mRNA expression and clinicopathological 
parameters in patients with triple-negative breast cancer 
Clinicopathological 
parameters 
KLK4a 
low/high 
KLK5b 
low/high 
KLK7c  
low/high 
KLK12d 
negative/ positive 
Age p=0.320 p=0.681 p=0.353 p=0.492 
≤ 60 years 45/19 42/22 43/18 35/26 
> 60 years 32/20 36/16 33/20 27/26 
Lymph node status p=0.127 p=0.189 p=0.595 p=0.215 
N0 47/18 47/18 40/22 37/25 
N1/N2/N3 30/21 31/20 38/16 25/27 
Tumor size p=0.969 p=0.453 p=0.936 p=0.731 
≤20 mm 20/10 22/8 20/10 17/13 
>20 mm 57/28 56/29 56/27 44/39 
Histological grade p=0.004 p=0.279 p=0.052 p=0.747 
Grade II 3/8 9/2 11/1 6/6 
Grade III 74/31 69/36 65/37 56/46 
a Chi-square test (dichotomized into low and high groups by the 67th percentile);  
b Chi-square test (dichotomized into low and high groups by the 67th percentile); 
c Chi-square test (dichotomized into low and high groups by the 67th percentile); 
d Chi-square test (dichotomized into negative and positive group). 
Bold values indicate statistical significance (p≤0.05), values in italics indicate a trend 
towards significance. 
 
4.2.3 Assessment of the prognostic impact of KLK mRNA expression and 
clinicopathological parameters on disease-free survival and overall survival in 
triple-negative breast cancer  
The impact of KLKs and the clinicopathological parameters on patient outcome (DFS 
and OS) was investigated applying univariate and multivariate Cox regression analyses 
in the TNBC cohort.  
As shown in Table 21, among the clinical parameters, age is a univariate prognostic 
factor for the patient outcome (DFS and OS). The patients in the advanced age subgroup 
(>60 years) have an elevated risk of cancer-related death (HR: 2.92, 95% CI: 1.61-5.30, 
p<0.001) as well as disease recurrence (HR: 2.35, 95% CI: 1.36-4.07, p=0.002). Lymph 
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node status (N0 vs. N+) is a univariate predictor for OS (HR: 1.78, 95% CI: 1.01-3.13, 
p=0.046), while it only approaches statistical significance for DFS (HR: 1.63, 95% CI: 
0.95-2.78, p=0.075). The KLK4 mRNA represents an unfavorable predictor for DFS 
(HR: 1.83, 95% CI: 1.03-3.26, p=0.040) and OS (HR: 2.07, 95% CI: 1.13-3.80, 
p=0.019), revealing an approximately two-fold increased probability of disease 
progression and cancer-related death in the high KLK4 mRNA expression subgroup. 
Patients with positive KLK12 mRNA expression experience an increased risk of 
disease relapse (HR: 2.15, 95% CI: 1.20-3.84, p=0.010) and cancer-related death (HR: 
2.00, 95% CI: 1.09-3.67, p=0.025), compared to the cases with negative KLK12 
expression. Neither KLK5 nor KLK7 mRNA levels contribute to the patient outcome 
in the TNBC cohort.  
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Table 21. Univariate Cox regression analysis of KLK mRNA expression and 
clinicopathological parameters for the prediction of clinical outcome in triple-negative 
breast cancer 
Clinicopathological 
parameters 
 DFS   OS  
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.002   < 0.001 
≤ 60 years 66 1  66 1  
> 60 years 56 2.35 (1.36-4.07)  57 2.92(1.61-5.30)  
Lymph node status   0.075   0.046 
N0 68 1  69 1  
N1/N2/N3 53 1.63 (0.95-2.78)  54 1.78 (1.01-3.13)  
Tumor size   0.130   0.118 
≤20 mm 32 1  32 1  
>20 mm 88 1.70 (0.86-3.39)  90 1.83 (0.86-3.92)  
Histological grade   0.762   0.956 
Grade II 12 1  12 1  
Grade III 109 1.15 (0.46-2.90)  111 1.03 (0.41-2.59)  
KLK4 mRNAc   0.040   0.019 
low 74 1  75 1  
high 38 1.83 (1.03-3.26)  39 2.07 (1.13-3.80)  
KLK5 mRNAd   0.945   0.651 
low 75 1  77 1  
high 37 1.02 (0.56-1.87)  37 0.86 (0.45-1.66)  
KLK7 mRNAe   0.544   0.847 
low 74 1  76 1  
high 37 1.21 (0.66-2.21)  37 1.07 (0.56-2.02)  
KLK12 mRNAf   0.010   0.025 
negative 59 1  61 1  
positive 52 2.15 (1.20-3.84)  52 2.00 (1.09-3.67)  
a Number of patients;  
b HR: hazard ratio (CI: confidence interval) of univariate Cox regression analysis;  
c Dichotomized into low and high groups by the 67th percentile; 
d Dichotomized into low and high groups by the 67th percentile; 
e Dichotomized into low and high groups by the 67th percentile; 
f Dichotomized into negative and positive groups; 
The bold value indicates statistical significance (p≤0.05). Italics indicate trends towards 
significance (p≤0.09). 
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The impact of KLKs on patient outcome was further validated by the respective Kaplan-
Meier survival analyses. As shown in Figure 17, overexpression of KLK4 mRNA is 
significantly correlated with shortened DFS (p=0.037) and OS (p=0.016) in TNBC 
patients. In line with the finding in univariate Cox analysis, KLK5 and KLK7 mRNA 
expression levels are not related to the prognosis (Figure 18). Patients with KLK12 
positive expression exhibit a significantly worse DFS (p=0.008) and OS (p=0.022), 
compared to the negative expression cases (Figure 19).  
 
Figure 17. Association of KLK4 mRNA expression with clinical outcome, analyzed by 
Kaplan–Meier survival analysis in tumor tissues of triple-negative breast cancer 
Patients with elevated KLK4 mRNA levels display a significantly shortened DFS (p=0.037; 
A) and OS (p=0.016; B), compared to those with low KLK4 mRNA levels. 
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Figure 18. Association of KLK5 and KLK7 mRNA expression with clinical outcome 
analyzed by Kaplan–Meier survival analysis in tumor tissues of triple-negative breast 
cancer  
Neither KLK5 nor KLK7 mRNA levels contribute to patient outcome in this TNBC 
cohort. 
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Figure 19. Association of KLK12 mRNA expression with clinical outcome, analyzed by 
Kaplan–Meier survival analysis in tumor tissues of triple-negative breast cancer 
Patients with KLK12 mRNA positive expression show a significantly worse DFS (p=0.008; 
A) and OS (p=0.022; B), compared those with KLK12 mRNA negative expression. 
 
Additionally, the independences of KLK4 (Table 22) and KLK12 (Table 23) in the 
prediction of prognosis were further investigated by the multivariate Cox regression 
analyses. Similar to the analyses in HGSOC, a base model was firstly established 
comprising age, lymph node status, tumor size, and histological grade. Upon addition 
to the base model (Table 22), KLK4 mRNA expression does not prove to be statistically 
significant, however, presents a trend towards significance for OS (HR: 1.83, 95% CI: 
0.96-3.49, p=0.067). As to KLK12 (Table 23), after adjustment for the base model, its 
mRNA expression remains an unfavorable prognostic biomarker for DFS (HR: 2.16, 
95% CI: 1.19-3.93, p=0.011), however, shows a trend towards significance for OS (HR: 
1.82, 95% CI: 0.97-3.41, p=0.060). In summary, KLK12 was demonstrated to be an 
independent predictive marker for DFS in TNBC. 
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Table 22. Multivariate Cox regression analysis of KLK4 mRNA expression and 
clinicopathological parameters for the prediction of clinical outcome in triple-negative 
breast cancer 
Clinicopathological 
parameters 
 DFS   OS  
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.001   < 0.001 
≤ 60 years 61 1  61 1  
> 60 years 50 2.64 (1.45-4.82)  52 3.50 (1.80-6.82)  
Lymph node status   0.198   0.115 
N0 62 1  63 1  
N1/N2/N3 49 1.47 (0.82-2.63)  50 1.66 (0.88-3.10)  
Tumor size   0.275   0.284 
≤20 mm 30 1  30 1  
>20 mm 81 1.51 (0.72-3.15)  83 1.57 (0.69-3.59)  
Histological grade   0.732   0.911 
Grade II 11 1  11 1  
Grade III 100 1.20 (0.42-3.39)  102 1.06 (0.37-3.03)  
KLK4 mRNAc   0.114   0.067 
low 74 1  75 1  
high 37 1.64 (0.89-3.04)  38 1.83 (0.96-3.49)  
The hazard ratios of tumor markers were adjusted for the base model, including age, lymph 
node status, tumor size, and histological grade. 
a Number of patients; 
b HR: hazard ratio (CI: confidence interval) of univariate Cox regression analysis;  
c Dichotomized into low and high group by the 67th percentile; 
Bold values indicate statistical significance (p≤0.05), values in italics indicate a trend 
towards significance. 
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Table 23. Multivariate Cox regression analysis of KLK12 mRNA expression and 
clinicopathological parameters for the prediction of clinical outcome in triple-negative 
breast cancer 
Clinicopathological 
parameters 
 DFS   OS  
Noa HR (95% CI)b p Noa HR (95% CI)b p 
Age   0.001   < 0.001 
≤ 60 years 59 1  59 1  
> 60 years 51 2.84 (1.54-5.24)  53 3.54 (1.81-6.90)  
Lymph node status   0.052   0.037 
N0 60 1  61 1  
N1/N2/N3 50 1.80 (0.99-3.24)  51 1.96 (1.04-3.67)  
Tumor size   0.246   0.220 
≤20 mm 30 1  30 1  
>20 mm 80 1.54 (0.74-3.21)  82 1.67 (0.74-3.79)  
Histological grade   0.757   0.947 
Grade II 12 1  12 1  
Grade III 98 1.16 (0.45-2.98)  100 1.03 (0.40-2.68)  
KLK12 mRNAc   0.011   0.060 
negative 58 1  60 1  
positive 52 2.16 (1.19-3.93)  52 1.82 (0.97-3.41)  
The hazard ratios of tumor markers were adjusted for the base model, including age, lymph 
node status, tumor size, and histological grade. 
a Number of patients; 
b HR: hazard ratio (CI: confidence interval) of univariate Cox regression analysis;  
c Dichotomized into negative and positive group; 
Bold values indicate statistical significance (p≤0.05), values in italics indicate a trend 
towards significance. 
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5 Discussion 
A growing body of evidence has implied the potential predictive values of KLKs in a 
variety of carcinomas, including prostate (Samaan et al., 2014), gastric (Jiao et al., 
2013), skin (Avgeris and Scorilas, 2016), colorectal (Alexopoulou et al., 2013), ovarian 
(Loessner et al., 2018) and breast (Avgeris et al., 2012) cancer. For instance, elevated 
KLK4 mRNA levels are associated with favorable outcome in laryngeal squamous cell 
carcinoma (Foteinou et al., 2014), while KLK4 overexpression represented an 
unfavorable predictor in oral (Papagerakis et al., 2015), prostate (Avgeris et al., 2011) 
and breast cancer (Yang et al., 2017). Both ovarian and breast cancer are heterogeneous 
diseases, of which the subtypes are distinct concerning morphology, biology, behaviors, 
and response to therapy (Jelovac and Armstrong, 2011; Cedolini et al., 2014). 
Conflicting results were often observed in previous studies, which may be ascribed to 
the heterogeneous patient cohorts analyzed, comprising different clinical stages and 
histological types. Thus, specific tumor biomarkers for different subgroups of ovarian 
and breast cancer to predict the course of disease and/or therapy response are in demand. 
To further investigate the clinical relevance of tumor-related KLKs, in the current study, 
we aimed at determining the mRNA expression levels of KLK4, KLK5, KLK7 and 
KLK12 and correlating their expression levels with clinical outcome in well-defined 
homogeneous cohorts, including 139 patients with advanced high-grade serous ovarian 
cancer and 125 patients with triple-negative breast cancer. 
5.1 Assessment of KLKs as potential prognostic biomarkers in advanced high-
grade serous ovarian cancer 
To date, several studies have reported that the expression levels of KLK4 (Dong et al., 
2001), KLK5 (Dorn et al., 2011) and KLK7 (Dong et al., 2003) are up-regulated in 
ovarian carcinomas compared to benign and/or low malignant potential (LMP) tumors, 
suggesting potential diagnostic values of these KLKs in ovarian cancer. Moreover, 
either at mRNA levels or at protein levels, KLK4 (Dong et al., 2001; Obiezu et al., 
2001), KLK5 (Kim et al., 2001; Diamandis et al., 2003) and KLK7 (Kyriakopoulou et 
al., 2003; Shan et al., 2006) were observed to be more frequently expressed in advanced 
stages and were associated with higher nuclear grade of ovarian malignancies. In the 
present study, we observed that the majority of tumor tissues displayed robust mRNA 
expression patterns of KLK5 and KLK7, while low KLK4 mRNA expression was 
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observed. These observations were consistent with data from The Cancer Genome Atlas 
(TCGA) (Loessner et al., 2018), which also reports low KLK4 mRNA expression levels 
and high expression levels of KLK5 and KLK7 mRNA in ovarian cancer.  
The antigen levels of KLK5 (Dorn et al., 2016) and KLK7 (Dorn et al., 2014), 
respectively, have also been quantified in a partially overlapping ovarian cancer cohort. 
In the present study, we demonstrate that KLK5 mRNA expression is significantly and 
positively associated with its protein expression (rs=0.689) in HGSOC, which has been 
further validated by box plot analysis. A similar association between KLK7 mRNA and 
protein expression was observed in our study (rs=0.663) as well.  
Prior studies have reported that KLK4 expression is highly expressed in the effusion 
fluid of serous epithelial ovarian cancer patients (Davidson et al., 2005; Dong et al., 
2013). In addition, Dong and co-workers (2013) observed that higher KLK4 levels are 
present in the ascites of serous epithelial ovarian cancer cells compared to primary 
tumor cells, also indicating its involvement in the ascites microenvironment of ovarian 
cancer. In accordance with this, in the present study, KLK4 mRNA levels were observed 
to be significantly correlated with the amount of pre-operative ascites fluid volume in 
our cohort. A remarkably increasing proportion of patients displayed higher KLK4 
mRNA expression in the subgroup with larger ascites fluid volume (>500 ml; 60%, 
32/53), compared to those with ascites fluid volume ≤500 ml (42%, 33/78). However, 
contrary results were reported by Shih et al. (2007), showing that KLK4 expression was 
generally low in effusion fluid of ovarian cancer patients, compared to benign effusions. 
This discrepancy may be attributed to the fact that the present study assessed the mRNA 
levels of KLK4 by qPCR, whereas Shih and co-workers (2007) determined secreted 
KLK4 protein expression by ELISA, implicating that KLK4 could be expressed in 
ovarian tumor cells but not be secreted to extracellular environment. All KLKs have 
been described to be highly conserved concerning exon number as well as exon/intro 
phases and show a high similarity of structure (Clements et al., 2001; Paliouras et al., 
2007). Interestingly, Korkmaz et al. (2001) found that KLK4 in prostate cancer, due to 
an alternative transcription initiation site, was the only member of the KLK family that 
lacks the characteristic first exon for coding signal peptide, which resulted in the 
retention of the physiologically related major form of KLK4 in the cell. This behavior 
of KLK4 exhibited a distinct perinuclear localization, which was dissimilar to the other 
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KLKs having major extracellular functions. 
Obiezu and co-workers (2001) have previously quantified KLK4 mRNA expression 
levels in a cohort containing 147 malignant ovarian tissues, showing that KLK4 mRNA 
overexpression was associated with shortened PFS and OS. There, elevated KLK4 
expression also represented an unfavorable predictor for prognosis in subset of ovarian 
cancer patients with lower grade (grade 1 and 2). Moreover, Dong et al. (2001) found 
that elevated KLK4 protein levels were connected with more aggressive histological 
subtypes and/or advanced stage of ovarian tumors, suggesting an association between 
KLK4 expression and the proliferative status of ovarian cancer. Furthermore, KLK4 
has been demonstrated as a predictive marker for paclitaxel resistance in patients with 
ovarian malignancies (Xi et al., 2004; Dong et al., 2013). These observations indicated 
that KLK4 may serve as a tumor biomarker for monitoring the progression and/or 
prognosis, but also as a therapeutic target in ovarian cancer. Consistent with this, in the 
present study, KLK4 mRNA expression was found to be an independent unfavorable 
predictor for poor OS, but not for PFS. In the in silico analysis (Gyorffy et al., 2012), 
high KLK4 mRNA levels were confirmed to be remarkably associated with shortened 
PFS and OS in this subtype of ovarian cancer. The lack of significant predictive power 
for PFS might be due to the relative low numbers of included samples in our cohort. 
KLK4 expression may thus turn out to represent a prognostic biomarker for PFS, if we 
enrolled more ovarian cancer cases. 
There are several possible mechanisms to explain the prognostic functions of KLK4 in 
ovarian cancer. Dong et al. (2001) have observed that KLK4 protein levels were 
increased by estrogen in the ovarian cancer cell line OVCAR-3. Consistent with this, 
several prior studies also reported that KLK4 mRNA expression was up-regulated by 
steroid hormones like androgen, estrogen, and progesterone in prostate cancer cells 
(Nelson et al., 1999; Xi et al., 2004) and by androgen as well as progestin in breast 
cancer cells (Yousef et al., 1999). Although the potential function of the steroid 
hormones in ovarian cancer is a matter of discussion, several studies have demonstrated 
their association with tumor progression of ovarian cancer (Høgdall et al., 2007; 
Jönsson et al., 2015; Feng et al., 2016). Thus, it may be hypothesized that KLK4 may 
perform through hormone-related regulatory mechanisms to promote tumor cell 
spreading in ovarian tumor. Moreover, several studies indicated that KLK4 promoted 
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tumor progression and metastasis by activating enzymatic cascades. In the PC-3 
prostate cancer cell line, the function of KLK4-accelerating tumor cell migration was 
shown to be related to the loss of E-cadherin and an epithelial-mesenchymal transition-
like effect (Veveris-Lowe et al., 2005). Additionally, KLK4 could also modulate the 
expression of secreted growth factors such as HGF/SF (Mukai et al., 2008, 2015), IGF 
(Matsumura et al., 2005) and TGF-β (Shahinian et al., 2014), which are involved in 
tumor progression, thus affecting tumor cell proliferation, invasion, angiogenesis, and 
metastasis. 
In case of KLK5, accumulating studies have demonstrated that it also represents a 
predictive biomarker in ovarian cancer. Kim et al. (2001) have investigated KLK5 
mRNA levels in the cohort containing 142 epithelial ovarian cancer cases, showing that 
elevated KLK5 mRNA expression was significantly associated with an increased risk 
of disease recurrence and cancer-related death. Moreover, Diamandis and co-workers 
(2003) have reported that KLK5 overexpression was correlated with unfavorable 
prognosis in ovarian cancer. Furthermore, KLK5 antigen levels have also been 
measured in serum of ovarian cancer patients, describing that KLK5 protein expression 
was higher in serum of ovarian cancer patients, compared to those of benign controls 
and LMP tumors (Bandiera et al., 2009; Dorn et al., 2011). A significant correlation was 
observed between high KLK5 protein levels and advanced disease stage in ovarian 
cancer (Bandiera et al., 2009). Moreover, elevated KLK5 protein expression was found 
to be associated with poor outcome of ovarian cancer patients, suggesting an 
unfavorable prognostic value of KLK5 in this tumor entity (Oikonomopoulou et al., 
2008; Dorn et al., 2011). Taken all together, KLK5 overexpression may represent an 
unfavorable prognostic biomarker and correlate with more aggressive phenotypes of 
ovarian cancer. However, contrary results were reported by Dorn and co-corkers (2016) 
assessing KLK5 protein levels in this tumor entity, showing that the overexpression of 
KLK5 by stromal cells, but not by tumor cells, was significantly correlated with 
prolonged PFS and OS. This finding suggested a tumor-suppressive function of KLK5 
in ovarian cancer, indicating that KLK5 may perform divergent functions in different 
cell types. 
In the current study, residual tumor mass was the only clinical variable correlated with 
KLK5 mRNA expression in HGSOC. Compared to the tumor-free subgroup (27%, 
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19/70), an enhanced proportion of high KLK5 mRNA levels was observed in the 
subgroup with residual tumor (44%, 29/66), pointing to a tumor-supporting role of 
KLK5. Furthermore, elevated KLK5 mRNA levels were significantly associated with 
shortened PFS in univariate analysis, however, only showed a trend towards 
significance when subjected to multivariable analysis. In line with our finding, in in 
silico analyses (Gyorffy et al., 2012), a significant association of higher KLK5 mRNA 
levels with worse PFS, but not OS, was observed in this subtype of ovarian cancer. 
These observations are in agreement with prior studies, which also showed an 
association of high KLK5 mRNA levels with poor PFS, rather than OS, in ovarian 
cancer (Zheng et al., 2007; Dorn et al., 2011, 2011). Nevertheless, in two separated 
studies by Kim et al. (2001) and Diamandis et al. (2003), respectively, KLK5 
overexpression was found to be associated with both worse PFS and OS of ovarian 
cancer patients. Whether these discrepancies are attributed to the heterogeneous patient 
cohorts encompassing low/high grade, early/advanced stage and different histological 
subtypes of ovarian cancer cannot be presently answered. 
The proposed molecular mechanism may explain the tumor-supporting role of KLK5 
in neoplasm. Homology studies from Yousef and Diamandis (1999) suggested that 
KLK5 was up-regulated by estrogen and progestin in breast cancer cell line BT-474. In 
Matrigel-based assays, siRNA-mediated KLK5 inhibition was shown to decrease the 
invasion of bladder cancer cells (Shinoda et al., 2007). Under physiological conditions, 
KLK5 is involved in skin desquamation by degrading the cell-cell and cell-matrix 
adhesion molecules. In fact, inhibition of KLK5 enforced cell-cell adhesion in oral 
squamous cell carcinoma, further increasing the metastatic speed by promoting loss of 
junctional integrity (Jiang et al., 2011). Therefore, the tumor-supporting role of KLK5 
in ovarian cancer may be attributed to the promotion of tumor cell shedding and the 
cleavage of ECM proteins during metastasis. Indeed, KLK5 was found to efficiently 
degrade various ECM proteins, including collagen I, II, III and IV, laminin and 
fibronectin (Michael et al., 2005). Furthermore, KLK5 targets a variety of substrates 
such as TGF-β and PARs, which upon (in-)activation by KLK5 modulate important 
tumor-associated signaling pathways (Oikonomopoulou et al., 2006; Paliouras and 
Diamandis, 2006). Moreover, KLK5 could also play a crucial role in the extracellular 
proteolytic network in tumor cell microenvironment through activating the zymogen 
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forms of other tumor-associated proteases, such as pro-uPA and pro-KLK11 (Beaufort 
et al., 2010a, 2010b).  
Regarding KLK7, it has been well described to be implicated in the desquamation 
process of skin in vivo as well (Lundström and Egelrud, 1991). Accumulating evidence 
further showed that KLK7 is up-regulated in ovarian (Dorn et al., 2006; Shaw and 
Diamandis, 2007; Psyrri et al., 2008), pancreatic (Avgeris et al., 2010), colon (Talieri 
et al., 2009) and cervix malignancies (Termini et al., 2010), whereas it is down-
regulated in kidney (Gabril et al., 2010), breast (Holzscheiter et al., 2006; Ejaz et al., 
2017) and prostate (Xuan et al., 2008) cancer..  
Additionally, KLK7 has been well described for its prognostic value in ovarian cancer. 
Psyrri et al. (2008) observed that elevated KLK7 protein expression was associated with 
inferior DFS and OS in ovarian cancer patients. A similar trend was reported by 
Kyriakopoulou et al. (2003) evaluating 125 ovarian tumor specimens, illustrating that 
KLK7 overexpression is an independent unfavorable predictor for DFS and OS in the 
subgroup of ovarian cancer patients with lower grades (grade 1+2). Furthermore, Shan 
and co-workers (2006) reported that elevated KLK7 antigen levels were more 
frequently observed in patients with advanced stage and higher-grade (G3), and were 
correlated with shortened PFS of ovarian cancer patients. Additionally, KLK7 has been 
shown to represent a predictive biomarker for paclitaxel chemoresistance in patients 
with serous epithelial ovarian carcinoma (Dong et al., 2010). All these evidence suggest 
a tumor-promoting role of KLK7 in ovarian malignancies. In line with previous studies, 
in the present study, elevated KLK7 mRNA expression was observed to be significantly 
associated with high risk of tumor progression and turned out to represent an 
independent unfavorable predictive biomarker in HGSOC.  
Nevertheless, a contrary result was reported by Dorn et al. (2014) analyzing KLK7 
antigen concentrations in tumor tissue extracts from 98 ovarian cancer patients by 
ELISA, showing that higher KLK7 protein expression was associated with prolonged 
PFS and OS, revealing that KLK7 may represent a favorable clinical determinant of 
prognosis in this tumor entity. The hypothesized explanation for this discrepancy might 
be attributed to the cohort analyzed by Dorn et al. (2014). Patients were of different 
subtypes of ovarian malignancies (serous, endometrioid, undifferentiated, mucinous, 
and clear cell types) and several cases were of earlier grades (FIGO I/II, 20%), whereas 
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the homogenous patient cohort in our study enrolled cases afflicted with HGSOC only. 
The pathophysiological function of KLK7 in ovarian tumors still needs to be further 
investigated. 
KLK7 has been proposed to mediate several signaling pathways to affect tumorigenicity. 
In epithelial ovarian carcinoma (EOC), KLK7 was shown to stimulate peritoneal 
dissemination and reinvasion through increasing multicellular aggregates (MCA) and 
α5/β1 integrin-dependent cell adhesion (Dong et al., 2010). Indeed, integrin signaling 
has been reported to be involved in MCA/spheroids formation (Casey et al., 2001) and 
disaggregation (Burleson et al., 2004), which could promote EOC cell invasion and 
metastasis (Auersperg et al., 2001; Bast et al., 2009). Furthermore, elevated α5 integrin 
levels were associated with unfavorable outcome of EOC patients (Goldberg et al., 
2001). Moreover, KLK7 has been demonstrated to cleave ECM proteins (Ramani and 
Haun, 2008) and/or junction/adhesion molecules including corneodesmosomes (Caubet 
et al., 2004), desmoglein-1 and desmocollin-1 (Ramani et al., 2008), which could lead 
to the detachment of tumor cells from the primary tumor and dissemination (McGary 
et al., 2002; Ganguly et al., 2013). These evidence indicate that KLK7 may facilitate 
tumor cell migration and invasion processes. Last but not least, Ramani et al. (2011) 
found that KLK7 was associated with the activation of matrix metalloproteinase-9 
(MMP-9) in tumors, influencing angiogenesis, tumor cell migration, invasion, and 
metastasis, further suggesting that KLK7 could be implicated in tumor development 
and progression.  
KLK12 mRNA expression was not detected in 35 samples of our cohort of HGSOC 
patients, which is in line with the data from TCGA (Loessner et al., 2018).  
Accumulating evidence has also demonstrated that the combined expression of KLK4-
7 is part of enzymatic cascades to accelerate progression and metastasis in ovarian 
cancer (Dong et al., 2014). Prezas et al. (2006) showed that simultaneous 
overexpression of KLK4-7 led to a remarkable increase of cell invasion in vitro and 
tumor burden in xenograft models of ovarian cancer. Moreover, the concomitant 
expression of KLK4-7 was observed to be associated with reduced cell adhesion and 
insensitivity to paclitaxel in ovarian cancer cells (Loessner et al., 2012). Thus, it is 
tempting to speculate that co-expression of KLK4-7 might be regulated through similar 
modulatory mechanisms in ovarian cancer. In fact, KLKs have been indicated to form 
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activation cascades by activating zymogen forms of other proteases, including other 
members of the KLK family (Yoon et al., 2007). Firstly, as noted in the previous 
sections, KLK4, KLK5, and KLK7 are regulated by steroid hormones in ovarian 
carcinomas. Secondly, KLK4-7 have a pronounced effect on the secreted proteome in 
OV-MZ-6 ovarian cancer cells, suggesting the capability of activating signaling 
cascades in tumor microenvironment of ovarian cancer, such as TGFβ and epithelial-
mesenchymal transition (EMT) pathways (Shahinian et al., 2014). Moreover, the data 
from Mukai et al. (2008) suggested that KLK4 and KLK5 represented novel factors to 
mediate the activation of pro-HGF/SF induced by hepatocyte growth factor activator 
(HGFA) within tumor tissues, indicating vital functions of KLK4 and KLK5 in the 
processes of tissue morphogenesis, regeneration, and tumor progression. Last but not 
least, a recent study revealed that KLK4-7 could modulate various cancer-related genes 
and proteins in ovarian cancer (Wang et al., 2018), including MSN, KRT7, KRT19, and 
JUNB, which are strongly associated with tumorigenesis, further supporting the 
important role of KLK4-7 in progression of this tumor entity. 
5.2 Clinical impact of KLKs mRNA expression on patients with triple-negative 
breast cancer 
As stated above, many members of the KLK gene family, including the four analyzed 
KLKs, were implicated in hormone-dependent tumors. As outlined in the previous 
chapter (5.1), we have evaluated the clinical impact of these KLKs on patient outcome 
in HGSOC, which may be modulated by steroid hormones-related regulatory 
mechanisms. Similarly, in breast cancer, KLKs could also play crucial roles in tumor 
progression and metastasis. However, to date, no research has correlated mRNA 
expression of these KLKs with patient outcome in TNBC, lacking the expression of ER 
and PR, and with no or low HER2 protein expression.  
In the present project, most of the TNBC specimens displayed low mRNA expression 
levels of KLK4 and KLK12, while robust KLK5 and KLK7 mRNA expression was 
observed, showing a very similar trend to the expression patterns observed in the 
HGSOC cohort. We observed that mRNA expression of these KLKs was not detectable 
in some tumor tissues of TNBC patients. This was especially notable for KLK12 with 
a high proportion of patients displaying negative expression (62/114, 54%).  
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Among the 15 members of KLK gene family, only expression of KLK4 was found to 
be upregulated, both at mRNA and protein levels, in breast malignancies, compared to 
normal breast tissues (Davidson et al., 2007; Papachristopoulou et al., 2009; Schmitt et 
al., 2013). Furthermore, elevated KLK4 mRNA levels were associated with advanced 
stage and higher tumor grade in a qPCR-based study including 16 benign and 45 
cancerous breast tissues (Papachristopoulou et al., 2009), suggesting that KLK4 
overexpression was associated with a more aggressive behavior of breast cancer cells. 
Additionally, KLK4 mRNA levels were significantly and negatively correlated with PR 
staining in this tumor entity, which was considered as a favorable indicator of hormone-
related breast cancer, indicating the unfavorable prognostic value of KLK4 in breast 
cancer (Papachristopoulou et al., 2009). Consistent with previous studies, in our study, 
a remarkably high proportion of patients exhibited elevated KLK4 mRNA levels in the 
subgroup with higher grade breast cancer (grade III; 70%, 74/105), compared to the 
cases with lower grade (grade II; 27%, 3/11), indicating that KLK4 may serve as a 
tumor-promoting biomarker in TNBC. Furthermore, in the present study, elevated 
KLK4 mRNA levels were significantly associated with shortened DFS and OS. A 
similar trend was previously reported by Yang et al. (2017) evaluating the protein data 
of KLK4 in 188 TNBC patients, illustrating that KLK4 overexpression in tumor-
associated stromal cells was associated with poor DFS, also suggesting that KLK4 
represented an unfavorable predictor in this tumor entity.  
To date, the potential molecular mechanisms of KLK4 promoting tumorigenicity have 
not been well defined. KLK4 has been described to be involved in the enzymatic 
cascade pathway to regulate the tumor microenvironment via PAR1/2 signaling or the 
uPA-plasminogen axis. KLK4 could initiate cell signaling through PARs in vitro, 
facilitating tumor cell proliferation, migration, invasion, and metastasis (Ramsay et al., 
2008). KLK4 could also accelerate tumor growth and development by activating uPA 
(Takayama et al., 2001), which was validated as an unfavorable indicator in breast 
cancer (Duffy et al., 2014; Dovnik and Takac, 2017). Additionally, KLK4 have been 
suggested to activate KLK3 by cleaving its precursor (pro-KLK3) (Takayama et al., 
2001), whereby active KLK3 could promote tumor invasion and metastasis by cleaving 
IGF-binding protein 3 (IGFBP3) (Cohen et al., 1994) and parathyroid-hormone-related 
protein (PTHRP) (Cramer et al., 1996; Iwamura et al., 1996).  
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Furthermore, a recent study indicated that KLK4 silencing suppressed tumor cell 
proliferation and enhanced apoptosis in oral squamous cell carcinoma cells through 
inhibition of the activation of Wnt/b-catenin signaling pathway (Cui et al., 2017). 
Moreover, KLK4 has been reported to activate MMP1 (Fuhrman-Luck et al., 2016), 
enhancing the prostate cancer cell growth, migration, invasion and metastasis in vitro 
(Pulukuri and Rao, 2008). KLK4 was also validated to be a tumor-promoting factor by 
liberating N-terminal fragments of thrombospondin-1 (TSP1) and directly cleaving 
TSP1 in prostate cancer (Fuhrman-Luck et al., 2016). Additionally, KLK4 has been 
found to cleave the extracellular domain of murine ephrin-B2 in the research of 3D 
protein models applying an in silico approach (Lisle et al., 2015). Ephrin-B2 is the 
single physiologically-relevant ligand of EphB4, which is a member of type 1 
transmembrane receptor tyrosine kinases and normally contribute to tumor suppression 
in many epithelial cancers, including breast cancer (Noren et al., 2006; Rutkowski et 
al., 2012; Barneh et al., 2013; Hu et al., 2014). Lisle and co-workers (2015) found that 
KLK4 may facilitate tumor invasiveness and angiogenesis by modulating EphB4-
ephrinB2 interactions via selectively cleaving murine ephrin-B2. All in all, KLK4 may 
represent a potential multifunctional modulator for tumorigenesis in TNBC. 
Regarding KLK5, it has been reported to exhibit the prognostic power in various 
carcinoma types. Shinoda et al. (2007) have reported that KLK5 levels were frequently 
upregulated in invasive bladder tumors, compared to superficial tumors, indicating the 
potential role of KLK5 to stimulate cell invasion in bladder carcinoma. In colorectal 
cancer, KLK5 overexpression was clearly associated with an advanced tumor stage, 
suggesting that KLK5 may represent a biomarker predicting tumor recurrence and 
metastasis in this tumor entity (Wu et al., 2016). Similarly, in a plethora of studies, 
KLK5 mRNA has been underlined the crucial effects on the progression of breast 
cancer and represented a predictor for the diagnosis and prognosis of breast cancer 
patients. In a RT-qPCR based study containing 102 breast cancer cases, KLK5 mRNA 
levels were found to be highly expressed in benign tumor specimens, compared to 
cancerous breast tumor specimens (Avgeris et al., 2011). Moreover, Yousef et al. (2002) 
have described that KLK5 overexpression was associated with reduced DFS and OS in 
179 patients with different stages and grades of breast malignancies, indicating an 
unfavorable predictive value of KLK5 in this tumor entity. Additionally, Yang and co-
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workers (2015) also reported a similar trend determining KLK5 protein levels in 180 
TNBC patients, illustrating that elevated KLK5 protein levels in tumor stromal cells 
were significantly associated with distal metastasis and shortened OS. Besides, KLK5 
expression was observed to be significantly increased in BT-20 breast cancer cells 
treated with docetaxel and methotrexate, suggesting that KLK5 may represent a 
potential indicator for predicting chemotherapy response (Papachristopoulou et al., 
2013). However, in view of our data, no significant correlation was observed between 
KLK5 mRNA expression and clinical outcome in the TNBC cohort.  
Likewise, in the current study, KLK7 also did not present any significant association 
with DFS or OS of TNBC patients. Nevertheless, it should be noted that KLK7 has 
been previously identified as a predictor in various malignancies, including breast 
cancer. In pancreatic cancer cells, inhibition of KLK7 was found to efficiently reduce 
pancreatic tumor cells proliferation, migration, and invasion, suggesting that KLK7 
may be a therapeutic target in this tumor entity (Du JP et al., 2018). In intracranial tumor 
cells, Prezas et al. (2006) have quantified KLK7 levels in a cohort containing 73 tumor 
tissue specimens, showing that KLK7 overexpression was associated with the increased 
invasion potential and worse OS. Additionally, higher KLK7 mRNA expression has 
been demonstrated to represent an unfavorable prognostic biomarker in colorectal 
cancer (Inoue et al., 2010). In breast cancer, KLK7 expression levels were found to be 
highly expressed in normal and benign tissues and under-expressed in cancerous tissues 
(Li et al., 2009; Ejaz et al., 2017). Talieri et al. (2004) have quantified KLK7 mRNA 
levels in 92 breast cancer tissues, showing that KLK7 overexpression was significantly 
associated with shortened DFS and OS, revealing an unfavorable prognostic effect in 
this tumor entity. However, Holzscheiter and co-workers (2006) have reported a 
contrary result in a population-based cohort containing 176 primary breast cancer 
patients, describing that KLK7 overexpression was a significant predictor of prolonged 
DFS.  
The potential explanation for these discrepancies for KLK5 and KLK7 may be due to 
the fact that the current study assessed KLK5 and KLK7 mRNA levels in the well-
defined cohort of TNBC patients, whereas the cohorts previously analyzed 
encompassed heterogeneous subtypes of breast cancer, including the ER and PR 
positive as well as negative cases. Secondly, it is hypothesized that the lack of 
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significant association may also be due to the rather low patient numbers. Further study 
is required to investigate their prognostic values in ovarian cancer. 
KLKs have been reported to be involved in the progression of malignancies by 
produced cancer-specific transcript forms (Xu and Lee, 2003; Kurlender et al., 2005; 
Tan et al., 2006). KLK12 was found to generate three alternative splice variants 
(KLK12sv1/2/3) (Yousef et al., 2000) and the classical form (Kurlender et al., 2005), 
which exhibited various physiological functions and displayed a key role in the 
progression of malignancies (Landry et al., 2003). In breast cancer cells, Yousef et al. 
(2000) observed that KLK12 mRNA expression was downregulated by steroid 
hormones. In the current study, we quantified all KLK12 transcripts in TNBC. Here, 
positive KLK12 mRNA expression was significantly associated with shortened DFS 
and OS in the univariate cox regression analysis and represented an independent 
unfavorable predictor for DFS in TNBC patients. Similar associations have also been 
observed in other tumor types. In gastric carcinoma, KLK12 overexpression was found 
to be significantly associated with more aggressive behaviors and patients with elevated 
KLK12 expression presented a significantly worse 5-year survival rate compared to 
those with low KLK12 levels (Zhao et al., 2012). KLK12 mRNA overexpression has 
also been shown to represent an unfavorable predictive biomarker for prognosis in 
pulmonary carcinoid (Swarts et al., 2013). These findings are in accordance with 
previous functional studies, which observed pro-tumorigenic role of KLK12 protease. 
Knockdown of KLK12 diminished proliferation and migration of gastric cancer cells 
by arresting cells in the G0/G1 phase (Zhao et al., 2012; Li et al., 2016). KLK12 could 
also promote cell migration by stimulating the proteolysis of the human extracellular 
matrix proteins fibronectin and tenascin, which are implicated in the regulation of 
endothelial cell adhesion and migration (Kryza et al., 2018). Furthermore, KLK12 has 
been described for its proangiogenic effect, thereby displaying a crucial role in the 
process of carcinoma. KLK12 was found to indirectly modulate the bioavailability 
and/or activity of various growth factors, such as VEGF165, BMP2, TGF-β1, and FGF-
2, via hydrolyzing matricellular proteins (Guillon-Munos et al., 2011), which are 
implicated in angiogenesis and tumorigenesis (Dallas et al., 2005). Additionally, 
KLK12 could also modulate the availability of platelet-derived growth factor B (PDGF-
B) via cleaving its C-terminal retention motif, stimulating tumor growth and 
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angiogenesis (Kryza et al., 2014). Last but not least, KLK12 is secreted as an inactive 
pro-enzyme, which autoactivates to acquire enzymatic activity. Moreover, KLK12 has 
been demonstrated to activate pro-KLK11 in vitro, suggesting that KLK12 might 
participate in the proteolytic cascades to facilitate specific physiologic processes 
(Borgoño and Diamandis, 2004; Memari et al., 2007).  
However, two research groups, which measured expression of distinct KLK12 
transcripts in breast cancer, have described contradictory observations of the prognostic 
value of KLK12 in this tumor entity. Talieri and co-workers (2012) found that 
KLK12sv3 overexpression was significantly associated with lower grade, earlier stages, 
and positive estrogen and progesterone receptor status. Patients with high KLK12sv3 
expression displayed longer DFS in breast cancer. Therefore, KLK12sv3 may be 
considered as a favorable indicator for prognosis in breast cancer but possibly not for 
TNBC owing to that this transcript is poorly or not expressed in ER and PR negative 
breast tumors (Talieri et al., 2012). Similarly, Papachristopoulou et al. (2018) also 
determined the potential functional role of distinct KLK12 splice variants in 122 tissue 
specimens from patients with the surgical removal of cancerous or benign breast tumors. 
There, both KLK12sv1/2 and KLK12sv3 overexpression predicted long-term DFS and 
OS for breast cancer patients. Thus, it seems likely that the overall expression of KLK12 
examined in our study mainly equates to the KLK12sv1/2 transcripts encoding this 
protease. Convergences between the prognostic effects of transcripts encoding either a 
KLK protease or an alternative transcript coding for a truncated form have also been 
reported for KLK8 in lung carcinoma (Planque et al., 2008), suggesting that the same 
KLK gene may probably generate two products with opposite functions in the process 
of neoplasm. Moreover, KLK12sv3 expression was found to be higher in benign breast 
tumors compared to cancerous breast tissues, and elevated KLK12sv3 levels were 
significantly associated with a more aggressive behavior in breast cancer cells 
(Papachristopoulou et al., 2018). Hence, all these observations indicate that KLK12 
exhibits a pro-tumorigenic role in breast carcinoma, whereas KLK12vs3, encoding a 
truncated protein lacking a functional catalytic triad, may play a tumor-suppressive 
function. Further studies would be necessary to examine this hypothesis. 
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5.3 Coordinate expression of KLK5 and KLK7 in advanced high-grade serous 
ovarian cancer and triple-negative breast cancer 
As mentioned above, in the present study, not only the parallel expression of KLK5 and 
KLK7 was observed in HGSOC and TNBC, but irrefutable evidence was observed for 
coordinated modulation of both KLKs concerning expression on the mRNA level 
(HGSOC: rs=0.568, p<0.001; TNBC: rs=0.735, p<0.001) and protein level (HGSOC: 
rs=0.805, p<0.001). This indicates that KLK5 and KLK7 may be implicated in 
synergistic or independent mechanisms contributing to tumor-related processes. Other 
KLKs, including KLK4, KLK6, KLK8, KLK9, KLK10, KLK11, KLK13, KLK14, and 
KLK15, exhibit weak associations with either KLK5 or KLK7 in the same ovarian 
cancer cohort (with rs<0.3; N. Ahmed, L. Dettmar, and X. Geng, pers. comm.). 
Likewise, prior studies from our lab determined co-expression of several other KLK 
pairs, such as KLK6 versus KLK8 (Ahmed et al., 2016), KLK9 versus KLK15 (Geng 
et al., 2017), and KLK10 versus KLK11 (Geng et al., 2017, 2018). The combination of 
KLK6 with KLK8 was found to aid in determining patients with prolonged survival 
(Ahmed et al., 2016), whereas the concomitant expression of KLK10 and KLK11 could 
identify patient outcome with better accuracy (Geng et al., 2018). Besides, the 
consistent expression of KLKs has also been identified in several other malignancies. 
Martins et al. (2011) reported a parallel under-expression of KLK6, 7, 8 and 13, 
highlighting a potential role of these KLKs in the transition of epithelial into 
mesenchymal in primary melanoma. Furthermore, the parallel overexpression of KLK7 
and KLK14 was observed in colon carcinoma, indicating their potential cascade-like 
implication in this tumor entity (Devetzi et al., 2013). All these findings point to an 
involvement of certain KLKs in shared cascades/pathways influencing the progression 
of malignancies. 
Concordant expression of KLK5 and KLK7 has been described in several human 
organs and tissues. It was initially observed in skin tissues, suggesting there may be a 
relationship between these two proteases (Brattsand and Egelrud, 1999; Ekholm et al., 
2000). Furthermore, KLK5, KLK7, and KLK14 were found in catalytically active form, 
resembling a proteolytic cascade, in the stratum corneum (Brattsand et al., 2005). 
Moreover, in Netherton syndrome, both KLK5 and KLK7 play important roles in 
inflammation, while simultaneous deficiency of both KLKs could rescue the epidermal 
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barrier and the postnatal lethality in a mouse model (Kasparek et al., 2017). Indeed, 
KLKs have been proposed to activate themselves and each other, thus initiating an 
activity amplification cascade in pathophysiological processes (Debela et al., 2008). 
For example, KLK4 could process the zymogens of KLK3 and KLK11 into their active 
counterparts (Takayama et al., 2001; Yoon et al., 2007). (pro-)KLK5 has been found to 
be auto-activated and then activate several pro-KLKs, including KLK2, KLK3, KLK6, 
KLK7, KLK12, and KLK14 (Brattsand et al., 2005; Michael et al., 2006; Blaber et al., 
2007; Yoon et al., 2007).  
Furthermore, cumulative evidence have implied cooperative interaction between KLK5 
and KLK7 in various neoplasms. In oral squamous cell carcinoma, concomitant 
inhibition of KLK5 and KLK7 was observed, which was associated with poor prognosis 
in this tumor entity (Leusink et al., 2015). In ovarian cancer, Dong and co-workers 
(2003) have reported that KLK5 and KLK7 were expressed abundantly in ovarian 
cancer, especially in advanced-stage serous tumors. They also found that KLK7 could 
reduce the surrounding matrix as the cancer progresses and verified the interaction 
between them in vitro in an activation cascade (Dong et al., 2003). Interestingly, the 
combined expression of KLK4, 5, 6 and 7 has been shown the potential to promote an 
increase of TGFβ-1 signaling and decrease of integrin and MAPK independent 
interactions, thereby diminishing cell adhesion and inducing cell invasion as well as 
resistance to paclitaxel in OV-MZ-6 ovarian cancer cells (Loessner et al., 2012; 
Shahinian et al., 2014). Similarly, in breast cancer, Talieri et al. (2011) observed parallel 
overexpression of KLK5 and KLK7 in a Greek population-based cohort containing 80 
breast tissues, while Li et al. (2009) found parallel under-expression of KLK5 and 
KLK7 in an Asian population-based cohort. The coordinated up- or down-regulation of 
KLK5 and KLK7 in breast cancer is potentially regulated by the same pathways, such 
as steroid hormones, thus contributing to carcinogenesis and tumor development 
(Yousef et al., 1999, 2000). Consistent with this, we showed that, both in HGSOC and 
in TNBC cohorts, KLK5 and KLK7 were coordinately expressed and both of them 
represented unfavorable predictive biomarkers in HGSOC, further supporting the 
hypothesis that KLK5 and KLK7 may be involved in an activation cascade and exhibit 
similar roles in the progression of malignancies.  
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6 Summary 
Kallikrein-related peptidases have been determined to be involved in both physiological 
and pathological processes, like skin desquamation, inflammation, and especially in 
tumor-relevant processes. High-grade serous ovarian cancer commonly presents with 
nonspecific or low sensitive symptoms and triple-negative breast cancer lacks specific 
molecular targets, both resulting in high mortality rates and limitation of therapy 
options. Several KLKs represent biomarkers for diagnosis and prognosis in ovarian and 
breast cancer. However, paradoxical observations of the effects of some KLKs on 
prognosis were often delineated in these tumor entities, which may be due to the rather 
heterogeneous patient cohorts previously analyzed. Therefore, the present project 
aimed at lighting up the promising roles of tumor-relevant KLK expression as 
prognostic biomarkers in more homogenous cohorts of patients with advanced high-
grade serous ovarian cancer and triple-negative breast cancer.  
In HGSOC, KLK4, 5, 7, and 12 mRNA expression levels were analyzed by quantitative 
PCR. Together with available protein data overlapping with the mRNA cohort, KLK5 
mRNA expression was found to be significantly and positively associated with the 
protein expression (rs=0.689, p<0.001). Similarly, KLK7 mRNA expression was also 
correlated with its protein levels (rs=0.663, p<0.001). These suggest that there is no 
major post-transcriptional regulation for the expression of KLK5 and KLK7. Therefore, 
the mRNA and protein data are comparable. Moreover, pronounced associations were 
observed between KLK5 and KLK7 both at the mRNA levels (rs=0.568, p<0.001) and 
the antigen levels (rs=0.805, p<0.001), strongly supporting that KLK5 and KLK7 are 
concomitantly expressed in this tumor entity. In univariate Cox regression analysis, 
patients with elevated KLK4 mRNA expression levels displayed shortened OS 
(HR=2.28, p=0.001), but did not show any significant difference in PFS. Higher KLK5 
mRNA expression was associated with worse PFS (HR=1.60, p=0.047), but not 
correlated with OS. Patients with elevated KLK7 mRNA levels exhibited an 
unfavorable prognosis of PFS (HR=1.75, p=0.025) and showed a trend towards 
significance in case of OS (HR=1.66, p=0.055). These results were further confirmed 
by in silico analysis based on the publicly available mRNA expression profiles from 
The Cancer Genome Atlas. In multivariate analysis, KLK4 turned out to be an 
independent unfavorable predictive biomarker of OS (HR=2.31, p=0.006), while KLK7 
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represented an independent unfavorable predictor of both PFS (HR=2.19, p=0.007) and 
OS (HR=1.94, p=0.032). KLK5 did not prove to be statistically significant, however, 
showed a trend towards significance for PFS (HR=1.53, p=0.095). 
In addition, we also quantified KLKs mRNA expression in a selected cohort containing 
125 TNBC patients. Tumor specimens of TNBC subgroup were characterized by a 
negative status for ER and PR, and by lack or low levels of HER2 protein expression. 
Patients with TNBC have the worst outcome among all breast cancer subtypes, due to 
the fact that the available anti-targeted therapy has very limited or no impact on this 
entity. In addition to the findings in HGSOC, a remarkable correlation between KLK5 
and KLK7 mRNA expression was also observed in TNBC (rs=0.735, p<0.001), 
indicating that the parallel and coordinated expression also exists in this tumor entity. 
Univariate Cox regression analysis showed that elevated KLK4 mRNA levels were 
significantly associated with shortened DFS (HR=1.83, p=0.040) and OS (HR=2.07, 
p=0.019), while KLK12 overexpression was also remarkably correlated with poor DFS 
(HR=2.15, p=0.10) and OS (HR=2.00, p=0.025). However, both KLK5 and KLK7 
mRNA expression did not show any predictive value in this subgroup of breast cancer. 
In multivariate analysis, KLK4 mRNA expression did not prove to be statistically 
significant, however, presented a tendency towards significance concerning prediction 
of OS (HR=1.83, p=0.067). Upon addition to the base model, KLK12 mRNA 
expression remained an unfavorable prognostic biomarker for DFS (HR=2.16, 
p=0.011), however, showed only a trend towards significance for OS (HR=1.82, 
p=0.060). 
In conclusion, KLK4, KLK5, KLK7, and KLK12 were investigated in HGSOC and 
TNBC, whether they can serve as prognostic biomarkers and may represent attractive 
targets for tumor therapy, showing the potential to assist in making decisions on 
systemic therapy for patients with poor prognosis in these tumor entities. Further studies 
aimed at determining the potential cancer-related pathways of which KLKs are 
involved in are warranted. This would guide the improvement of cancer intervention 
strategies and help patients suffering from these malignancies.   
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9 Appendix 
9.1 Ovarian cancer FIGO and TNM stage systems 
9.1.1 Ovarian cancer FIGO stage system 
Stage Description 
I Tumor limited to ovaries or fallopian tube(s). 
IA 
Tumor limited to one ovary (capsule intact) or fallopian tube; no tumor on 
ovarian or fallopian tube surface; no malignant cells in the ascites or 
peritoneal washings. 
IB 
Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on 
ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal 
washings. 
IC Tumor limited to one or both ovaries or fallopian tubes, with any of the following: 
IC1 Surgical spill intraoperatively. 
IC2 Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface. 
IC3 Malignant cells in the ascites or peritoneal washings. 
II Tumor involves one or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer 
IIA Extension and/or implant on uterus and/or fallopian tubes and/or ovaries 
IIB Extension to other pelvic intraperitoneal tissues 
III 
Tumor involves one or both ovaries, or fallopian tubes, or primary peritoneal 
cancer, with cytologically or histologically confirmed spread to the peritoneum 
outside of the pelvis and/or metastasis to the retroperitoneal lymph nodes. 
IIIA Metastasis to the retroperitoneal lymph nodes with or without microscopic peritoneal involvement beyond the pelvis. 
IIIA1 Positive retroperitoneal lymph nodes only (cytologically or histologically proven). 
IIIA1(i) Metastasis ≤10 mm in greatest dimension, 
IIIA1(ii) Metastasis >10 mm in greatest dimension. 
IIIA2 Microscopic extra-pelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. 
IIIB Macroscopic peritoneal metastasis beyond the pelvic brim ≤2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes. 
IIIC Macroscopic peritoneal metastases beyond the pelvic brim >2 cm in greatest dimension, with or without metastases to the retroperitoneal nodes. 
IV Distant metastasis excluding peritoneal metastases 
IVA Pleural effusion with positive cytology 
IVB Metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). 
Adapted from Mutch and Prat, 2014. 
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9.1.2 Ovarian cancer TNM stage system 
Stage T N M 
IA T1a N0 M0 
IB T1b N0 M0 
IC T1c N0 M0 
IIA T2a N0 M0 
IIB Tab N0 M0 
IIIA T3a N0 M0 T3a N1 M0 
IIIB T3b N0 M0 T3b N1 M0 
IIIC T3c N0 M0 T3c N1 M0 
IV Any T Any N M1 
Adapted from Mutch and Prat, 2014. 
9.1.3 Ovarian cancer grading system 
Grade Description 
GX:  Grade cannot be evaluated (undetermined grade) 
G1 Well-differentiated (low grade) 
G2 Moderately differentiated (intermediate grade) 
G3  Poorly differentiated (high grade) 
G4 Undifferentiated (high grade) 
Adapted from Edge and Compton, 2010 (Edge and Compton, 2010).  
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9.2 Breast cancer TNM-staging system according to American Joint Committee 
on Cancer (AJCC)  
9.2.1 T Classifications (Primary tumor) 
Category Definition 
TX Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
Tis (DCIS) Ductal carcinoma in situ 
Tis (Paget) 
Paget disease of the nipple NOT associated with invasive carcinoma and/or 
carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in 
the breast parenchyma associated with Paget disease are categorized based on 
the size and characteristics of the parenchyma disease, although the presence 
of Paget disease should still be noted. 
T1 Tumor ≤20 mm in greatest dimension. 
T1 mi Tumor ≤1 mm in greatest dimension. 
T1a Tumor >1 but ≤5 mm in greatest dimension (round any measurement >1.0-1.9 mm to 2 mm). 
  T1b Tumor >5 mm but ≤10 mm in greatest dimension. 
T1c Tumor >10 mm but ≤20 mm in greatest dimension. 
T2 Tumor >20 mm but ≤50 mm in greatest dimension. 
T3 Tumor >50 mm in greatest dimension. 
T4 
Tumor of any size with direct extension to the chest wall and/or to the skin 
(ulceration or macroscopic nodules); not including invasion of the dermis 
alone. 
T4a Extension to the chest wall; not including only invasion or adherence to pectoralis muscle  
T4b 
Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema 
(including peau d'orange) of the skin that does not meet the criteria for 
inflammatory carcinoma 
T4c Both T4a and T4b are present.  
T4d Inflammatory carcinoma. 
Adapted from Hortobagyi et al. 2017.  
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9.2.2 N Classification (Lymph node status) 
Clinical definition (cN) 
Category Definition 
cNX Regional lymph nodes cannot be assessed. 
cN0 No regional lymph node metastasis (by imaging or clinical examination). 
cN1 Metastasis to movable ipsilateral Level I, II, axillary lymph node(s). 
cN1 mi Micrometastases (approximately 200 cells, >0.2 mm but ≤2.0 mm). 
cN2 
Metastases in ipsilateral level I II axillary lymph nodes that are clinically fixed 
or matted;  
or in ipsilateral internal mammary nodes in the absence of axillary lymph node 
metastases. 
cN2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures. 
cN2b Metastases only in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. 
cN3 
Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with 
or without level I, II axillary lymph node involvement;  
or in ipsilateral internal mammary lymph node(s) with level I, II axillary lymph 
node metastases; 
or metastases in ipsilateral supraclavicular lymph node(s) with or without 
axillary or internal mammary lymph node involvement. 
cN3a Metastases in ipsilateral infraclavicular lymph node(s). 
cN3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s). 
  cN3c Metastases in ipsilateral supraclavicular lymph node(s). 
Adapted from Hortobagyi et al. 2017.  
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Pathological definition (pN) 
Category Definition 
pNX Regional lymph nodes cannot be assessed. 
pN0 No regional lymph node metastasis identified or ITCs only. 
pN0(i+) ITCs only (malignant cell clusters ≤0.2 mm) in regional lymph node(s). 
  
pN0(mol+) 
Positive molecular findings by reverse transcriptase-polymerase chain 
reaction (RT-PCR); no ITCs detected. 
pN1 
Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically 
negative internal mammary nodes with micrometastases or macrometastases 
by sentinel lymph node biopsy. 
pN1 mi Micrometastases (approximately 200 cells, >0.2 mm but ≤2.0 mm). 
pN1a Metastases in 1-3 axillary lymph nodes, at least one metastasis >2.0 mm. 
  pN1b Metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs. 
pN1c pN1a and pN1b combined. 
pN2 
Metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal 
mammary lymph nodes by imaging in the absence of axillary lymph node 
metastases. 
  pN2a Metastases in 4-9 axillary lymph nodes (at least one tumor deposit >2.0 mm). 
  pN2b 
Metastases in clinically detected internal mammary lymph nodes with or 
without microscopic confirmation; with pathologically negative axillary 
nodes. 
pN3 
Metastases in 10 or more axillary lymph nodes;  
or in infraclavicular (Level III axillary) lymph nodes; 
or positive ipsilateral internal mammary lymph nodes by imaging in the 
presence of one or more positive Level I, II axillary lymph nodes; 
or in more than 3 axillary lymph nodes and micrometastases or 
micrometastases by sentinel lymph node biopsy in clinically negative 
ipsilateral internal mammary lymph nodes; 
or in ipsilateral supraclavicular lymph nodes; 
pN3a 
Metastases in 10 or more axillary lymph nodes (at least one tumor 
deposit >2.0 mm); 
or metastases to the infraclavicular (Level III axillary) lymph nodes. 
  pN3b 
pN1a or pN2a in the presence of cN2b (positive internal mammary nodes by 
imaging); 
or pN2a in the presence of pN1b. 
  pN3c Metastases in ipsilateral supraclavicular lymph nodes. 
ITCs: Isolated tumor cell clusters. Adapted from Hortobagyi et al. 2017.  
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9.2.3 M classification (Distant metastasis) 
Category Definition 
M0 No clinical or radiographic evidence of distant metastases. 
  cM0(i+) 
No clinical or radiographic evidence of distant metastases in the presence of 
tumor cells or deposits <0.2 mm detected microscopic or by molecular 
techniques in circulating blood, bone marrow, or other non-regional nodal 
tissue in a patient without symptoms or signs of metastases 
cM1 Distant metastases detected by classic clinical and radiographic means. 
pM1 Any histologically proven metastases in distant organs; or if in non-regional nodes, metastases >0.2 mm. 
Adapted from Hortobagyi et al. 2017.  
9.2.4 AJCC stage group 
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1 mi M0 T1 N1 mi M0 
IIA 
T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
IIB T2 N1 M0 T3 N0 M0 
IIIA 
T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
IIIB 
T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
Adapted from Hortobagyi et al. 2017.  
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10 Abbreviations 
ACPT acid phosphatase 
AJCC American Joint Committee on Cancer 
AR androgen receptor 
Asp aspartic 
BMP bone morphogenic protein 
cDNA  complementary deoxyribonucleic acid  
CI confidence interval 
Ct cycle threshold 
DFS disease-free survival 
DMEM dulbecco’s modified eagle’s Medium 
DMSO dimethyl sulfoxide 
dNTP  deoxyribonucleoside triphosphate  
E efficiency 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGF epidermal growth factor 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assays 
EMSP1 enamel matrix serine proteinase 1 
EMT epithelial-mesenchymal transition 
EOC epithelial ovarian cancer 
EP error propagation 
ER estrogen receptor 
FBS fetal bovine serum 
FGF fibroblast growth factor 
FIGO Féderation Internationale de Gynécologie et d’Obstétrique 
FISH fluorescence in situ hybridization 
GFP green fluorescent protein 
HER2 the human epidermal growth factor receptor 2 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGFA hepatocyte growth factor activator 
HGF/SF hepatocyte growth factor/scatter factor 
HGSOC high-grade serous ovarian cancer 
His histidine 
HPRT  hypoxanthine-guaninephosphoribosyltransferase 
HR hazard ratio 
HSCCE human stratum corneum chymotryptic enzyme 
IGF insulin-like growth factor 
IGFBPs insulin-like growth factor binding proteins 
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kDa kilo Dalton 
KLK kallikrein-related peptidase 
KLK1 tissue kallikrein 
KLKB1 plasma kallikrein 
L1CAM cell adhesion molecule L1 
LMP low malignant potential 
M distant metastasis 
MAPK mitogen-activated protein kinases 
MCA multicellular aggregates 
MMP matrix metalloproteinase 
N regional lymph nodes 
NEOC non-epithelial ovarian cancer 
NSCLC non-small cell lung cancer 
OS overall survival 
PARs protease-activated receptors 
PBS phosphate-buffered saline 
PDGF-B platelet-derived growth factor B 
PFS progression-free survival 
PR progesterone receptor 
PSA prostate-specific antigen 
PTHRP parathyroid-hormone-related protein  
qPCR  quantity polymerase chain reaction  
RNA  ribonucleic acid 
RT  reverse transcription 
RT-PCR real-time polymerase chain reaction 
SDs standard deviations 
Ser serine 
SFTI-FCQR sunflower trypsin inhibitor  
SIGLEC9 sialic acid-binding Ig-like lectin 9  
siRNA small interfering RNA 
SNP single nucleotide polymorphism 
STDEV standard deviation 
T the primary tumor 
TCGA The Cancer Genome Atlas 
TGF-ß transforming growth factor-beta 
TNBC triple-negative breast cancer 
TSP1 thrombospondin-1 
TUM Technical University of Munich 
uPA urokinase plasminogen activator 
uPAR urokinase plasminogen activator receptor 
UTR untranslated region 
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VEGF vascular endothelial growth factor 
WHO the World Health Organization 
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